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1 Introduction 
1.1 Pattern Recognition Receptors in Innate Immunity 
Key to the establishment of an immune response is the discrimination between “self” and 
“non self” components within an organism. To this end, specific pathogen-associated 
molecular patterns (PAMPs) have to be recognized. Vertebrates have evolved two 
complementary systems to defend themselves against infection by pathogens, the innate and 
the adaptive immune response. Activation of the innate immune system is the initial response 
to invading pathogens and in most cases sufficient to clear the infection. Innate immunity is 
characterized by its ability to recognize a wide range of pathogens such as viruses, bacteria 
and fungi through a limited number of germline-encoded receptors called pattern recognition 
receptors (PRRs). In principle, fast evolving pathogens could escape recognition by PRRs by 
changing their targeted PAMPs. Therefore, the innate immune system recognizes PAMPs 
that are highly conserved throughout microbial species and essential for viability, such as 
sugars, flagellin or the cell wall components peptidoglycan and lipopolysaccharide (LPS). An 
important viral PAMP is double stranded RNA, which is an intermediate in viral replication 
and is not found in uninfected cells. In case the innate immune system is overwhelmed, the 
danger signals produced by the innate immune reaction also trigger the adaptive immune 
response. In adaptive immunity specific recognition is achieved by B and T effector cells 
which can express an indefinite number of receptors. These are created by somatic gene 
rearrangement and hypermutation. A detailed discussion of the adaptive immune system is 
given by Janeway and colleagues (Janeway et al. 2004).  
Over the past decade several types of PRRs have been identified (Table 1). Probably the 
best characterized PRRs are Toll-like receptors (TLRs) which are single-pass 
transmembrane proteins, localizing either to the plasma membrane or to endosomal 
compartments. In humans more than ten different TLRs with varying ligand-specificities have 
been described (Gay and Gangloff 2007; Kawai and Akira 2007; O'Neill and Bowie 2007). 
These receptors are composed of an ectodomain, which consists of multiple leucine-rich 
repeats (LRRs) that form a characteristic horseshoe fold, a single transmembrane spanning 
domain and a Toll/IL-1 receptor homology (TIR) domain which faces the cytosol. Current 
models assume, that TLRs are activated through a ligand-induced dimerization of the 
receptors which brings the cytosolic TIR domains in close proximity (Jin and Lee 2008). This 
allows for the recruitment of adaptor molecules, such as MyD88, TRIF and TIRAP which 
trigger the downstream signaling process. In addition to TLRs, scavenger receptors (SRs) 
are another type of PRRs which face the extracellular compartment. They are anchored to 
the cell membrane and are primarily found on macrophages to mediate phagocytosis 
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(Areschoug and Gordon 2009). Another important function of SRs is that they act as co-
receptors to TLRs, recognizing the same microbial patterns and feeding into the analog 
signaling cascades. 
Recognition of PAMPs in the cytosol is mainly carried out by two recently identified classes of 
proteins, the NOD-like receptors (NLRs) and RIG-I like receptors (RLRs). Structurally, NLRs 
are multidomain proteins with a tripartite architecture containing a C-terminal region 
characterized by a series of LRRs, a central nucleotide domain termed the NACHT domain 
and an N-terminal effector domain (Martinon et al. 2009). The LRR domain has been 
implicated in ligand sensing, whereas the NACHT domain oligomerizes in an ATP-dependent 
manner which is necessary for activation of the protein and downstream signaling (Martinon 
and Tschopp 2004; Faustin et al. 2007). The N-terminal effector domains, which in most 
cases are either caspase activation and recruitment domains (CARDs) or pyrin domains 
(PYD), mediate signal transduction to downstream targets. The tertiary structures of PYDs 
and CARDs are structurally related and are known as the “death fold”, as they are often 
found in pathways that lead to the activation of caspases or the activation of the transcription 
factor NF-κB (Park et al. 2007). Usually, a death domain of one type will interact with another 
death domain of similar type (e.g. either CARD/CARD – or PYD/PYD-interactions). Therefore 
the death fold acts as a “molecular velcro” that anchors adaptor and effector proteins to 
signaling platforms such as the NOD-signalosome or the inflammasome. 
The second important class of intracellular PRRs are the RIG-I like helicases. In contrast to 
the Toll-like PRRs described above, RIG-I like receptors lack repetitive receptor elements 
such as LRRs which could serve as recognition platform. Therefore, the finding that RIG-I 
like helicases were involved in viral sensing in the cytoplasm was unexpected (Yoneyama et 
al. 2004). The most prominent members of this receptor family are RIG-I (retinoic acid 
inducible gene I) and MDA5 (melanoma differentiation associated antigene 5), which share a 
similar domain architecture (Figure 1). Both proteins are composed of two N-terminal 
tandem CARDs, which act as adaptor domains analogous to CARDs in NLRs. LGP2 
(Laboratory of Genetics and Physiology 2) is the third member of the RLR family. In contrast 
to RIG-I and MDA5 it lacks the N-terminal adaptor CARDs (Figure 1). All three receptors 
however harbor a central DExD/H box helicase domain which is characterized by seven 
conserved motifs (I – also known as Walker A, Ia, II also known as walker B, III IV, V and VI). 
This domain is implicated in ATP binding and hydrolysis as well as RNA binding. Importantly, 
intact ATPase activity is essential for downstream signaling (Yoneyama et al. 2004). 
Recently, three groups independently described a cysteine-rich C-terminus in RIG-I, which is 
also conserved in MDA5 and LGP2 (Saito et al. 2007; Cui et al. 2008; Takahasi et al. 2008). 
This domain was found to inhibit RIG-I activation in the absence of viral stimulation. 
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Furthermore, experiments partially performed within the scope of this thesis identified it as a 
crucial recognition domain for viral RNA. As it is an important regulator of RIG-I activity the 
newly-characterized C-terminal domain was termed regulatory domain (RD). 
Table 1: Overview of pattern recognition receptors 
 
Figure 1: Domain organization of RIG-I like receptors.  
RIG-I and MDA5 are composed of two N-terminal tandem CARDs, a central DECH helicase motif and a C-
terminal RD domain. LGP2 lacks the N-terminal CARDs but otherwise shows a homologous domain 
architecture. 
 Location & function Protein motifs References 
Surface-PRRs    
Toll-like receptors Single-pass transmembrane 
proteins in the extracellular 
or endosomal membranes. 
Recognition of various 
components from viruses, 
bacteria, protozoa and fungi. 
Extracellular leucine rich 
repeats (LRR), single 
transmembrane domain, 
intracellular TIR domain. 
(Gay and Gangloff 
2007; Kawai and Akira 
2007; O'Neill and Bowie 
2007) 
Scavenger receptors Receptors found on 
phagocytotic cells. Enable 
phagocytosis of pathogens. 
No conserved domain 
architecture. Functional 
domains include collagenous 
helices, coiled coils and 
cysteine-rich regions as well 
as C-type lectin domains. 
(Areschoug and Gordon 
2009) 
Intracellular PPRs    
NOD-like receptors Cytosolic receptors inducing 
a NFκB and caspase 1 
dependent immune 
response. 
N-terminal effector domain 
(CARD), Pyrin Domain (PYD) 
or Baculovirus IAP Repeat 
(BIR)), central NACHT 
domain and C-terminal LRR. 
(Martinon et al. 2009) 
RIG-I like receptors Cytosolic RNA helicases 
inducing an NFκB and IRF1 
/ 3 dependent immune 
response. 
N-terminal tandem CARD, 
DECH box helicase motif, 
regulatory domain (RD). 
(Yoneyama and Fujita 
2009) 
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The structure of RIG-I RD and the homologous part in LGP2 structure were determined by X-
ray crystallography (Cui et al. 2008; Li et al. 2009; Pippig et al. 2009). Both structures are 
very similar and can be superimposed with only slight differences in the flexible loop regions 
(Figure 2). The RD is a flat domain with a convex and a concave side. It is organized into 
three antiparallel β-sheets which are connected by two protruding loops. The loops harbor 
four conserved cysteines which coordinate a zinc atom. The integrity of this zinc binding site 
is essential for correct folding and functioning of the RD. Analysis of the electrostatic surface 
potential identified a positively charged patch, which in both RDs localizes to a similar area 
on the concave side of the molecule (Figure 6, Figure 19). Since RIG-I recognizes 5’-
triphosphate RNA, which carries a high negative charge, the positive charged patch 
presumably functions as an RNA recognition site (Cui et al. 2008). 
 
Figure 2: Comparison of RD X-ray structures from RIG-I and LGP2. 
Ribbon model of RIG-I and LGP2 RD alone and superimposed with annotated secondary structure, zinc ion 
(sphere) and zinc-coordinating cysteines (sticks). Adapted from Cui et al 2008 and Pippig et al 2009. 
1.2 RIG-I and MDA5: Virus Sensing and RNA Structures 
Recognized 
In order to reproduce themselves once they have entered a cell, viruses must transcribe and 
replicate their genome. During these processes viral RNA is present in the cytoplasm and 
could function as a major danger signal for the cell. However in order to recognize this signal, 
the cell has to be able to discriminate between the viral RNA and the vast amount of self 
RNA, which in the cytoplasm is mainly constituted of mRNA and tRNA. One epitope specific 
to certain viral RNAs is the 5’-triphosphate modification, while in contrast, termini from 
cellular tRNA and mRNA are usually modified or have masking proteins bound (Bowie and 
Fitzgerald 2007). Two groundbreaking studies have demonstrated that the 5’-triphosphate 
motif of single stranded RNA (ssRNA) is crucial for RIG-I induced antiviral signaling (Hornung 
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et al. 2006; Pichlmair et al. 2006). RIG-I recognizes a series of ssRNA negative-strand 
viruses such as Hepatitis C Virus (HCV) and Measles Virus, which are known to produce 5’-
triphosphate RNA intermediates. In addition to 5’-triphosphate RNA as potent stimulator of 
RIG-I, there is accumulating evidence that double-stranded RNA (dsRNA), another known 
viral pattern, is also important for RIG-I activation. In particular, RIG-I can be activated with 
dsRNA in vitro as well as in vivo in a 5’-triphosphate independent manner (Yoneyama et al. 
2004; Cui et al. 2008). 
Whereas significant progress has been made over the past years to identify the RIG-I 
ligands, the physiological ligand for MDA5 remains enigmatic. It has been shown that MDA5 
is essential for the production of interferon in response to Picornaviruses, such as 
Encephalomyocarditis Virus (EMCV) (Kato et al. 2006). However, exactly which molecular 
patterns are recognized remains to be clarified. It is know that 5’-triphosphates on RNA are 
not necessary for MDA5 specific detection since Picornaviruses harbor a priming protein 
which masks RNA 5’-ends (Ambros and Baltimore 1978). Moreover, poly I:C, an synthetic 
dsRNA mimic, is a very potent activator of MDA5 in vivo and in vitro (Kato et al. 2006). This 
enzymatically synthesized polymer of undefined length has been known for decades to be a 
very potent stimulator of interferon (Colby and Chamberlin 1969). The length of the I:C 
polymer seems to be an important criterion for MDA5 activation. Whereas short poly I:C < 
1kbp is primarily sensed by RIG-I, dsRNA > 2kbp is exclusively recognized by MDA5 (Kato et 
al. 2008). So far, no convincing correlation between molecular features of the synthetic poly 
I:C and the physiological, MDA5-stimulating PAMPs from Picornaviridae could be found.  
1.3 LGP2: A Regulator of RIG-I and MDA5 Signaling 
LGP2 preferentially binds to dsRNA independent of triphosphate modifications (Murali et al. 
2008; Li et al. 2009; Pippig et al. 2009). Binding to dsRNA is mediated through a positively 
charged patch on the RD. The helicase domain also harbors a dsRNA binding site. It is 
currently unclear how the RNA binding specificity found in vitro correlates with the detection 
of viral RNA intermediates in infected cells in vivo. Due to its lack of CARDs, LGP2 is unable 
to induce antiviral signaling directly. However, several studies suggest how LGP2 could relay 
its signal by indirect means. On the one hand, LGP2 seems to have a positive regulatory 
impact on MDA5 signaling. On the other hand, it functions as a negative regulator of RIG-I 
mediated signal transduction (Rothenfusser et al. 2005; Komuro and Horvath 2006; 
Venkataraman et al. 2007). Whereas the negative regulation of RIG-I might be explained by 
a simple sequestration of dsRNA ligand, the positive regulation of MDA5 signaling suggests 
that the two proteins interact directly, or through a signaling pathway. However, a direct 
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interaction between MDA5 and LGP2 has not yet been detected in vitro. It is clear that the 
controversial roles of LGP2 in antiviral signaling are important targets for future studies. 
1.4 Downstream of RIG-I and MDA5: Transduction and 
Regulation of Antiviral Signaling  
CARDs act as molecular adaptors to mediate interactions with other CARD containing 
proteins. This knowledge narrowed down considerably the number of potential downstream 
adaptors for RLRs. Interferon-β Promoter Stimulator 1 (IPS-1), also known as Mitochondrial 
Antiviral Signaling (MAVS), Virus-Induced Signaling Adaptor (VISA) and CARD adaptor 
Inducing IFN-β (CARDIF) were identified by four groups independently to be the adaptors for 
RIG-I and MDA5 mediated signaling (Kawai et al. 2005; Meylan et al. 2005; Seth et al. 2005; 
Xu et al. 2005). IPS-1 is located on the outer mitochondrial membrane and consists of an N-
terminal CARD followed by a proline rich region (PRR) close to the N-terminus and a single 
C-terminal transmembrane domain. Activated RIG-I and MDA5 are thought to interact with 
IPS-1 via their CARDs thereby inducing recruitment of downstream signaling molecules. 
Several tumor necrosis factors (TNFs) and receptor-associated factors (TRAFs) directly 
interact with IPS-1 and transmit signals to downstream protein kinases of the inhibitor of NF-
κB kinase (IKK) family. The IKKs are then essential for the activation of the transcription 
factors IRF-3/7 and NF-κB. These transcription factors ultimately induce the production of 
type I interferons and inflammatory cytokines (Figure 3). 
Activation of RLR signaling has detrimental consequences for the cell and the entire 
organism. Therefore, it is very important that false positive signaling is prevented. Despite 
this, very small amounts of viral RNA have to be detected over the vast amount of self RNA. 
In addition, once the infection has been cleared, the antiviral response needs to be down-
regulated promptly. It is therefore obvious that this highly sensitive viral RNA detection 
system must include a vast array of both positive and negative regulatory proteins. Recent 
work revealed that post-translational modification, in particular ubiquitination, of RIG-I is 
important for its signaling capacity. Tripartite motif protein 25 (TRIM25), an E3 ubiquitin 
ligase, specifically interacts with the first CARD of RIG-I and conjugates Lys-63-linked 
ubiquitin chains to the Lys172 residue within the second CARD (Gack et al. 2007). These 
authors demonstrated that TRIM25 activity is needed for direct interaction of RIG-I with IPS-1 
and successful signal transduction. Interestingly, MDA5 signaling is independent of TRIM25-
mediated ubiquitination. In contrast to TRIM25, which is a positive regulator of RIG-I 
signaling, the ubiquitin ligase Ring Finger 125 (RNF125) downregulates RIG-I signaling 
(Arimoto et al. 2007). In this case, Lys-48-linked polyubiquitination in the N-terminal portion of 
RIG-I and MDA5 induces their proteasomal degradation. Recently, conjugation of ubiquitin-
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like ISG15 proteins to RIG-I was described as yet another negative regulatory mechanism 
(Arimoto et al. 2008). 
 
Figure 3: Virus sensing by RLRs in the cytoplasm and subsequent signal transduction. 
RIG-I and MDA5 sense RNA from different types of viruses. They interact with the mitochondrial adaptor 
protein IPS-1 to set off a signaling cascade finally resulting in the production of NFκB and IRF3/7. These 
transcription factors induce production of inflammatory cytokines and type I interferons (IFNs). Adapted from 
Yoneyama and Fujita 2009. 
Since the CARDs are essential for RLR signaling, these domains are a primary target for the 
regulation of antiviral signaling. LGP2, which lacks CARDs and thus cannot induce an 
interferon response per se, has been implicated to regulate RIG-I and MDA5 activity (chapter 
1.3). A detailed scheme of regulatory factors which influence RLR signaling is shown in 
Figure 4. 
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Figure 4: Regulators and viral inhibitors of RLR signaling. 
Posttranslational modifications of RIG-I and MDA5 such as ubiquitination by RNF125 or TRIM25 are critical for 
a tight regulation of the antiviral response. Kinases and other protein factors (fading grey spheres) influence 
RLR signaling on almost every level of signal transduction. The third helicase LGP2 has both positive and 
negative regulatory roles on MDA5 and RIG-I, respectively. The RIG-I splice variant (RIG-I SV) is a negative 
regulator of RIG-I signaling. Several viral proteins (dark grey boxes) interfere with critical components of the 
RLH signaling pathway.  
1.5 Inhibition of RLR Signaling by Viral Proteins 
Viruses have evolved a multitude of strategies to evade the host immune response. One 
mechanism of viral evasion is the interference of viral proteins with components of the host’s 
interferon response. For example, V-proteins of Paramyxoviridae have been shown to 
directly bind and inhibit MDA5-dependent interferon signaling (Andrejeva et al. 2004; Childs 
et al. 2007). Interestingly, the interaction with V-protein seems to be highly specific for MDA5, 
with RIG-I signaling remaining unaffected. Moreover, no direct interaction between RIG-I and 
V-protein could be described. V protein targets MDA5 via its highly conserved cysteine-rich 
C-terminal domain. Recently it was reported that V-protein binds to a region within the MDA5 
helicase domain and inhibits activation of MDA5 by blocking dsRNA binding (Childs et al. 
2008). Besides MDA5, V-protein interacts with several other cellular components. For 
example, V-protein-mediated connection of host proteins, such as STAT1 and STAT2, to the 
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DDB1-Cul4A-Roc1 E3 ubiquitin ligase complex leads to their specific ubiquitination and 
proteolytic destruction and thus interferes with the antiviral immune response (Horvath 2004). 
In addition to the inhibition of MDA5 by V-protein, several other viral proteins have been 
shown to specifically counteract central players in RLR signaling. Nonstructural protein 1 
(NS1) of influenza A virus interacts with RIG-I and inhibits its function (Guo et al. 2007). NS1, 
besides its direct influence on RIG-I, also has RNA binding activity and thereby conceals 
RLR stimulators (Figure 4). A similar inhibitory function has been attributed to nonstructural 
protein 2 (NS2) which interacts with the N-terminal portion of RIG-I (Kaukinen et al. 2006). 
The viral protease NS3/4 specifically cleaves IPS-1 at Cys508 and inactivates this important 
signaling adaptor (Figure 4). An even more direct strategy to evade recognition by the RLR 
detection system is the sequestering of viral RNA by viral proteins. Along these lines 
Picornaviridae encode a VPg protein which is covalently linked to triphosphate termini and 
thereby masks potential RIG-I activators (Figure 4) (Ambros and Baltimore 1978).  
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1.6 Objectives 
RIG-I like receptors are PRRs which sense viral RNA in the cytoplasm. Our laboratory was 
able to solve the crystal structure of the C-terminal RIG-I RD which was shown to be critical 
for the binding of 5’-triphosphate (Cui et al. 2008). It was, however, unclear how RIG-I 
recognizes viral RNA at the molecular level. In addition, the function of RD in the context of 
the full-length protein, in particular how RD synergistically functions together with other parts 
of the protein, was unknown and needed to be addressed experimentally. The fact that all 
RLRs harbor a DECH-box helicase motif suggested that these receptors may be endowed 
with helicase- (unwinding of nucleic acids) or translocation- (movement on nucleic acids) 
activity. Furthermore, it was in our greatest interest to structurally and functionally compare 
RIG-I to MDA5, the less-well characterized homologous receptor. Interestingly, MDA5 but not 
RIG-I function can be inhibited by V-proteins from Paramoyxoviridae. The molecular 
mechanism behind this specific inhibition was, however, also completely enigmatic. 
Therefore, the aim of this PhD thesis was to functionally dissect individual domains of RIG-I 
by performing biochemical studies. The binding site of 5-triphosphate ssRNA on RIG-I RD 
was to be mapped by a structure-guided mutagenesis approach and RNA binding studies. In 
addition, a detailed analysis of RIG-I ATPase activity was performed to give insights into the 
functional contribution of individual domains. To complement these biochemical studies, the 
potential helicase activity of RIG-I was tested on single-molecule level. Furthermore, 
functional studies of MDA5 and Paramyxovirus V-protein aimed to shed light on the 
molecular basis of the physiological MDA5 ligand and how exactly protein factors are able to 
inhibit MDA5. Finally, structural analysis of the MDA5 RD should allow a direct comparison to 
the homologous domain in RIG-I and might help explain the different ligand specificities. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Chemicals 
All common chemicals were obtained from Merck (Darmstadt, Germany), Roth (Karlsruhe, 
Germany) and Sigma (Deisenhofen, Germany), unless otherwise stated. Enzymes and 
nucleotides for molecular biology were supplied by MBI Fermentas (St. Leon-Rot, Germany). 
Chromatographic media and columns as well as radiolabel led nucleotides (γ-32P-ATP) were 
purchased from GE Healthcare (Freiburg, Germany). DNA oligonucleotides for cloning were 
ordered from Eurofins MWG (Munich, Germany). RNA for crystallization and activity assays 
was acquired from Biomers (Ulm, Germany). Poly I:C for MDA5 activity tests was purchased 
from Sigma (Deisenhofen, Germany). RIG-I and MDA5 cDNA for molecular cloning of 
expression constructs were received from RZPD (Heidelberg, Germany). 
2.1.2 Bacterial Strains 
Table 2: Bacterial strains 
E.coli strain Genotype Source 
XL1 Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ 
proAB lacIqZ∆M15 Tn10 (Tetr)] 
Stratagene, Heidelberg 
Rosetta (DE3) F– ompT hsdSB(rB– mB-) gal dcm (DE3) pRARE2 
(CamR) 
Novagen, Madison USA 
DH10MultiBac not specified Imre Berger (Berger et al. 
2004) 
 
2.1.3  Plasmids 
Table 3: Utilized plasmids 
Plasmid Expression System Source 
pET21b(+) E.coli Novagen, Madison USA 
pET28b(+) E.coli Novagen, Madison USA 
pCool (modified 
pGEX) 
E.coli Ning Zheng (Li et al. 2006) 
pFBDM Insect cells Imre Berger (Berger et al. 2004) 
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2.1.4 Media and Supplements 
Luria Broth (LB) liquid media as well as LB Agar plates were prepared according to standard 
protocols (Sambrook et al. 1989). The media was supplemented with the respective 
antibiotics using stock solutions in 1:1000 dilutions (Table 4). 
Table 4: Antibiotic stock solutions 
Antibiotic Concentration (1000x) Solvent 
Ampicilin (Na-Salt) 100 mg/ml water 
Kanamycin 50 mg/ml water 
Chloramphenicol 50 mg/ml ethanol 
Tetraycline 12.5 mg/ml ethanol 
Genatmycin  10 mg/ml  water 
 
Insect cell media powder (Express Five) was purchased from Invitrogen (Karlsruhe, 
Germany) and solubilized according to the manufacturer’s protocol. Before use, the media 
was supplemented with gentamycin (10 µg/ml) and glutamine (final concentration 18 mM). 
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2.1.5 Oligonucleotides 
Table 5: DNA oligonucleotides used for molecular cloning 
Name Sequence in 5’ to 3’ orientation 
RIG-I K858A for GCAGTTTTCAAGTTTTGAAGCAAGAGCAAAGATATTCTGTG 
RIG-I K858A rev CACAGAATATCTTTGCTCTTGCTTCAAAACTTGAAAACTGC 
RIG-I K888A for CATTTGAGATTCCAGTTATAGCAATTGAAAGTTTTGTGGTGG 
RIG-I K888A rev CCACCACAAAACTTTCAATTGCTATAACTGGAATCTCAAATG 
RIG-I H830A for GTAAGAGTGATAGAGGAATGCGCTTACACTGTGCTTGGAGATG 
RIG-I H830A rev CATCTCCAAGCACAGTGTAAGCGCATTCCTCTATCACTCTTAC 
RIG-I I875A for CAGCCATGACTGGGGAGCCCATGTGAAGTACAAG 
RIG-I I875A rev CTTGTACTTCACATGGGCTCCCCAGTCATGGCTG 
RIG-I D836A for CATTACACTGTGCTTGGAGCTGCTTTTAAGGAATGCTTTG 
RIG-I D836A rev CAAAGCATTCCTTAAAAGCAGCTCCAAGCACAGTGTAATG 
RIG-I K807A for CCTGATAAGGAAAATAAAGCACTGCTCTGCAGAAAGTGC 
RIG-I K807A rev GCACTTTCTGCAGAGCAGTGCTTTATTTTCCTTATCAGG 
MDA5 Sal1 for AAAAAAGTCGACATGTCGAATGGGTATTCCACAGAC 
MDA5 Not1 r 6his AAAAAAGCGGCCGCTCAATGATGATGATGATGATGATCCTCATCACTAAATAAACAGCAT
TC 
MDA5 Nhe1 287 for AAAAAAGCTAGCATGGGAAGTGATTCAGATGAAGAGAA 
MDA5 BamH1 897 
rev 
AAAAAAGGATCCTCACTTGTAATGCTTGGCAATATTTCTCTTG 
MDA5 BamH1 1025 
rev 
AAAAAAGGATCCCTAATCCTCATCACTAAATAAACAGCATTC 
MDA5 897 Nde1 for TGCCGCGCGGCAGCCATATG AAGAATAACCCATCACTAATAACTTTCC 
MDA5 Not1 rev TGGTGCTCGAGTGCGGCCGCCTAATCCTCATCACTAAATAAACAGCATTC 
V measles NdeI 49 
for 
AAAAAACATATGACCTGCAGGGAAGAGAAGGCA 
V measles  NotI rev AAAAAA GCGGCCGCTTATTCTGGGATCTCGGGGAGG 
Table 6: RNA Oligonuleotides used for functional assays 
Name Origin Sequence in 5’ to 3’ orientation 
pppRVL in vitro 
trans-
cription 
pppCUUAACAACCAGAUCAAAGAAAAAACAGACAGCGUCAAUGGCAGAGCAAAAA
UGU 
dsRNA for * synthetic  ACGCUUAACAACCAGAUCAAAGAAAAAACAGACAGCGUCAAUGGCAGAGC 
dsRNA rev* synthetic GCUCUGCCAUUGACGCUGUCUGUUUUUUCUUUGAUCUGGUUGUUAAGCGU 
3’P synthetic ACGCUUAACAACCAGAUCAAAGAAAAAp 
short I:C for 
* 
synthetic AAAAA CCCCCCCACCCCCCC AAAAA 
short I:C for 
mismatch * 
synthetic AAAAA CCCUCCCACCCUCCC AAAAA 
short I:C 
rev 
synthetic UUUUUU IIIIIIIUIIIIIII UUUU 
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*Complementary single stranded oligos were annealed by heating them to 95°C for 5 min 
followed by gradually cooling them down to 20°C with a temperature decrease of 0.5°C per 
min using a thermocycler. 
2.2 Methods 
2.2.1 Bioinformatic Methods 
2.2.1.1 Sequence Alignments 
Multiple sequence alignments were built with ClustalW2 (http://www.ebi.ac.uk/Tools 
/clustalw2 /) and visualized using Esprit (http://espript.ibcp.fr/ESPript/ESPript/index.php). 
2.2.1.2 Calculation of Protein Parameters 
Physical and chemical parameters of the recombinant proteins like molecular weight, 
(theoretical) isoelectric point (pI) and extinction coefficients were calculated with ProtParam 
(Wilkins et al. 1999) from the ExPASy Proteomics Server 
(www.expasy.org/tools/protparam.html). 
2.2.1.3 Structure Visualization and Analysis 
Structural visualization was achieved with PyMol Calculation (http://www.pymol.org) and 
electrostatic surface calculated using the APBS plugin for PyMol (Baker et al. 2001). 
2.2.1.4 Structural Homology Modeling 
Comparative structural homology modeling was performed with MODELLER (Eswar et al. 
2008) using the Bioinformatic Toolkit accessible online at http://toolkit.lmb.uni-muenchen.de 
(Biegert et al. 2006). 
2.2.2 Molecular Biology Methods 
2.2.2.1 Oligonucleotide Design and Polymerase Chain Reaction (PCR) 
PCR Primers for cloning genes of interest were designed using GeneRunner (Hastings 
software, USA). In general, the oligonucleotides used had a region complementary to the 
amplified DNA end of 20-25 nucleotides with a melting temperature (Tm) between 68°-72°C, 
and an attached restriction endonuclease site with a 6 poly(A) overhang to assure efficiency 
of restriction endonuclease cleavage. RIG-I and MDA5 cDNA was amplified by PCR using 
Phusion Flash Master Mix (Finnzymes, Espoo, Finnland). Primer concentration was 0.5 pM 
each, and approximately 1 ng of template DNA was added to each reaction. The final volume 
of each reaction was 20 µl. Each thermocycling program used 30 cycles, with times and 
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temperatures of denaturation, annealing and elongation varied to achieve optimal 
amplification. PCR products were purified from agarose gels using a Gel Extraction Kit 
(Metabion, Martinsried, Germany). 
2.2.2.2 Site-Directed Mutagenesis 
Point mutations were introduced by PCR using the quick change protocol (Kunkel 1985). 
Two synthetic oligonucleotide primers containing the desired mutation were extended during 
temperature cycling with Phusion polymerase. Incorporation of the oligonucleotide primers 
generated a mutated plasmid containing staggered nicks. A typical thermocycling procedure 
consisted of a 15 sec denaturation step at 98°C, a 30 sec annealing step at 58°C and a 5 
min extension step at 72°C. A complete run typically consisted of 20 repetitive cycles. 
Following temperature cycling, the product was treated with Dpn I to remove methylated 
template DNA and the reaction mixture was then transformed into competent XL1 blue cells. 
2.2.2.3 Restriction Cleavage and Ligation 
DNA was digested using restriction endonucleases and corresponding buffers (Fermentas, 
St. Leon-Rot, Germany) as recommended by the manufacturer. Digested products were 
purified using a Gel Extraction Kit (Metabion, Matrinsried, Germany). Cleaved vector DNA 
was additionally treated with calf intestine alkaline phosphatase (Fast AP, Fermentas, St. 
Leon-Rot, Germany) to prevent self-ligation. For ligation, a five- to tenfold excess of the 
digested DNA fragment was incubated with linearized vector and T4 DNA-ligase (Fermentas, 
St. Leon-Rot, Germany) in a 20 μl reaction according to the manufacturer’s instructions. 
2.2.2.3 Transformation of E. coli and Isolation of Plasmid DNA 
Transformation of plasmid DNA into competent E. coli cells was performed by mixing 100 μl 
of competent cells with 10 μl of the ligation reaction or 1 µl of purified plasmid DNA (40 ng/μl) 
and incubating on ice for 20 min. Cells were heat-shocked at 42°C for 45 sec and 
immediately afterwards chilled on ice. 1000 μl of fresh LB medium was added, followed by 
incubation at 37°C for 45 min in a shaking incubator. Cells were plated on LB agar plates 
containing the respective antibiotics and incubated at 37°C overnight. Plasmid DNA was 
isolated from a 5 ml overnight culture using the Plasmid Extraction Kit (Metabion, 
Matrinsried, Germany). DNA-sequencing of wild-type and mutant clones was performed by 
Eurofins MWG (Munich, Germany). 
2.2.2.4 Bacmid Preparation for Expression in Insect Cells 
Plasmid DNA of expression constructs was transformed into chemical competent 
DH10MultiBac cells as described previously (Section 2.2.2.3). After heat shock at 42°C and 
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cooling on ice, cells were incubated in a shaking incubator for 6-12 hours at 37ºC then plated 
on agar plates, containing the appropriate antibiotics (Kanamycin, Gentamycin, Tetracyclin) 
plus X-α-galactose (100 µg/ml) and IPTG (40 µg/ml). Plates were incubated at 37°C for 48 h. 
Successful integration of the gene of interest into the bacmid was assessed by blue / white 
screening. White colonies were used to inoculate an overnight shaking culture of 100 ml LB 
plus respective antibiotics. Cells were harvested by centrifugation and the bacmid isolated 
using the Midi-Prep Kit (Qiagen, Hilden, Germany), following the instructions provided by the 
manufacturer.  
2.2.2.5 Electrophoretic Separation of DNA 
DNA was separated in horizontally poured 1 % (w/v) Agarose/1x TAE gels containing 0.7 
μg/ml ethidium bromide (Roth, Karlsruhe, Germany) in the appropriate gel chamber filled with 
1x TAE buffer (40 mM Tris, 20 mM Acetic Acid, 1 mM EDTA). Before loading, samples were 
mixed with 6X Loading dye (Fermentas, St. Leon-Rot, Germany). DNA was visualized using 
a standard ultraviolet transilluminator (λ =254 nm, Eagle Eye, Stratagene, LaJolla, USA). 
2.2.3 Cell Culture Methods 
2.2.3.1 Protein Expression in E. coli 
For the over-expression of recombinant proteins, competent E. coli Rosetta (DE3) cells 
(Novagen, Schwalbach, Germany) were transformed with plasmid DNA carrying the gene of 
interest. Cells were grown at 37°C in LB medium in the presence of the appropriate 
antibiotics to an OD600 of 0.6-0.8. Protein expression was induced by the addition of IPTG 
(Roth, Karlsruhe, Germany) to a final concentration of 0.5 mM. After further growth overnight 
at 18°C, cells were harvested by centrifugation at 4°C. Cell pellets were flash frozen in liquid 
nitrogen and stored at -80°C. 
2.2.3.2 Protein Expression in Insect Cells  
Freshly diluted High Five insect cells (Invitrogen, Karlsruhe, Germany) were seeded in a 6-
well tissue culture plate (0.5 x 106 cells per well). Typically, cells were infected with 5 µg of 
bacmid DNA mixed with 3 µl of FuGENE HD Transfection Reagent (Roche, Penzberg, 
Germany) according to the manufacturer’s protocol. After incubation of the infected cells for 
48-60 h at 27.5 °C, the supernatant (viral generation 0 - V0) was collected. The viral titer was 
amplified by infecting 50 ml of freshly resuspended High Five insect cells at a concentration 
of 0.5 x 106 cells / ml with 3ml of V0. Cells were cultured for 72 - 96 h in 500 ml flasks at 
27.5 C with shaking at 85 rpm. During the incubation the cell density was monitored at 
regular intervals and cells were split below 2 x 106 cells/ml until cell proliferation arrested. 
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The supernatant (V1) was harvested by centrifugation and the cell material used for small 
scale purification. Large scale expressions were performed by incubating 1-5 L of freshly 
resuspended High Five insect cells (cell density: 0.5 x 106 cells/ml) with 20 - 50 ml of higher 
generation virus (V≥1). Cells were cultured in 5L flasks (maximum 1L per flask) at similar 
conditions as described for viral titer amplification. 48 h after cell proliferation had ceased, 
cells were harvested by centrifugation, flash frozen in liquid nitrogen and stored at -80°C. 
The supernatant containing high viral titers was utilized for further expression. 
2.2.4 Protein Biochemistry Methods 
2.2.4.1 Protein separation by SDS-PAGE 
Protein samples were analyzed by SDS-PAGE using 15% (v/v) polyacrylamide gels using the 
vertical Mini-PROTEAN 3 System (BIO-RAD, Munich, Germany). Before loading, samples 
were mixed with 4x loading dye and heated at 95°C for 2 min. After electrophoresis in 
electrophoresis buffer (190 mM Glycine, 50 mM tris, 0.1% (w/v) SDS), gels were stained with 
Coomassie staining solution (50% (v/v) ethanol, 7% (v/v) acetic acid, 0.2% (w/v) Coomassie 
Brilliant blue R-250) and destained with water. 
2.2.4.2 Protein Purification 
All buffers and their components used for protein purification are listed in Table 7 
For purification, cell pellets were resuspended in lysis buffer and disrupted by sonication. Cell 
debris was removed by centrifugation. His-tagged constructs were first purified using Ni-NTA 
Agarose (Qiagen, Hilden, Germany) packed in a gravity flow cartridge (BIO-RAD, Munich, 
Germany). After loading of soluble extracts, the resin was washed with Ni-NTA washing 
buffer. Protein was then eluted with Ni-NTA elution buffer. GST-tagged SV5 V-protein 
complexed with His-tagged MDA5 was further purified in a second affinity purification step 
using a GST-sepharose column (GE Healthcare, Freiburg, Germany). After capturing and 
washing with GST washing buffer, the complex was eluted with GST elution buffer. 
According to the theoretical pI (see chapter 2.2.1.2) all proteins were then further purified 
using anion- or cation- exchange columns (Table 8). The ion exchange column was 
equilibrated with low salt buffer and after loading, the protein was eluted with a gradient of 20 
column volumes from low- to high salt buffer. Peak fractions were pooled, concentrated with 
centrifugal devices (Amicon® Ultra, Millipore, Billerica, USA) and loaded onto a Superdex 
S200 26/60 size exclusion chromatography column (GE Healthcare, Freiburg, Germany) 
previously equilibrated with gel filtration buffer. Peak fractions were concentrated to greater 
than 5 mg/ml, flash frozen in liquid nitrogen and stored at -80°C.  
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Table 7: Protein purification buffers  
Buffer Composition 
Lysis buffer 50 mM Tris 7.5, 400 mM NaCl, 20 mM Imidazol, 10 mM β-mercaptoethanol, 1 mM 
PMSF 
Ni-NTA washing buffer 50 mM Tris 7.5, 400 mM NaCl, 20 mM Imidazol, 10 mM β-mercaptoethanol,  
Ni-NTA elution buffer 50 mM Tris 7.5, 100 mM NaCl, 200 mM Imidazol, 10 mM β-mercaptoethanol,  
GST washing buffer 50 mM Tris 8.0, 150 mM NaCl, 1mM DTT, 
GST elution buffer 50 mM Tris 8.0, 150 mM NaCl, 20 mM glutathione, 1mM DTT 
Low salt buffer 50 mM Tris 7.5, 100 mM NaCl, 1mM DTT, 100 µM ZnCl2 
High salt buffer 50 mM Tris 7.5, 1000 mM NaCl, 1mM DTT, 100 µM ZnCl2 
Gel filtration buffer 50 mM Tris 7.5, 150 mM NaCl, 5mM DTT, 100 µM ZnCl2 
 
Table 8: Purification strategy for used protein constructs 
Protein construct Purification steps 
RIG-I full length Ni-NTA, Q-sepharose, S200 gelfiltration 
RIG-I helicase domain Ni-NTA, Q-sepharose, S200 gelfiltration 
RIG-I-Δ-CARD Ni-NTA, Q-sepharose, S200 gelfiltration 
RIG-I SV Ni-NTA, Q-sepharose, S200 gelfiltration 
MDA5-FL Ni-NTA, Q-sepharose, S200 gelfiltration 
MDA5- Δ-CARD Ni-NTA, Q-sepharose, S200 gelfiltration 
SV5 V-protein MDA5 complex Ni-NTA, GST-sepharose, Q-sepharose, S200 gelfiltration 
MDA5 RD Ni-NTA, S-Sepharose, S200 gelfiltration 
RIG-I RD Ni-NTA, S-Sepharose, S200 gelfiltration 
 
2.2.5 Functional Protein Assays 
2.2.5.1 ATPase Assays 
The RNA-stimulated ATPase assays were performed in a 50 μl reaction volume containing 
100 mM Tris pH 7.5, 100 mM NaCl, 5 mM MgCl2, 100μg/ml bovine serum albumin (BSA), 1 
mM DTT, 0.1 - 5 mM ATP, 20 nM γ-32P-ATP (3000 Ci/mmol, Amersham Bioscience) and 0.1 
μM stimulatory RNA (in case of RIG-I: pppRVL, in case of MDA5 poly I:C or other synthetic 
RNA. After equilibration of the sample to 37°C, the reaction was started by addition of protein 
(typically 0.1 μM). A time course of ATP hydrolysis was made by removing 1 µl aliquots in 
constant intervals and directly spotting onto a thin layer chromatography polyethyleneimine-
cellulose plate (Merck, Darmstadt). Rapid air-drying of the spotted reaction mixture ensured 
that the reaction was stopped immediately. The thin-layer chromatography (TLC) plate was 
developed in 0.5 M LiCl / 1.0 M formic acid and subsequently air dried. The amount of educt 
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and product (ATP and liberated γ-32P, respectively) were visualized with a Phosphorimager 
(Amersham Bioscience) and quantified using Image Quant software. Initial reaction velocities 
were determined by plotting the amounts of hydrolyzed γ-phosphate against time and 
performing a linear regression with Origin analysis software. Enzymatic efficiencies were 
calculated by fitting the initial velocities by non-linear regression according to a modified 
Michaelis Menten model using the following equation:  
 
[ ] [ ][ ] M
Mcat
KATP
ATPKkenzymeactivity
/1
/
+
×=  
2.2.5.2 RNA Binding Assay by Fluorescence Anisotropy Measurements 
Fluorescent anisotropy measurements were performed using a FluoroMax-P fluorimeter 
(HORIBA Jobin Yvon, Unterhachingen, Germany) equipped with a Glan-Thompson prism 
polarizer and connected to a Haake F3 thermostat (Thermo Haake, Karlsruhe, Germany). 
Typically, 1.5 ml of buffer (20 mM Tris pH 7.5, 150 mM NaCl, 10 µM ZnCl2, 1mM DTT) and 50 
nM fluorescently labeled RNA (in vitro transcribed pppRVL with incorporated Alexa Fluor 488-
5-UTP) were pre-equilibrated in a quartz cuvette at 12°C. The protein was added in a 
stepwise manner and briefly mixed by magnetic stirring. After 3 min re-equilibration, 
anisotropy data were collected using an excitation wavelength of 492 nm and monitoring the 
emission at 512 nm. The band pass was 5 mm for excitation and 5 mm for emission. A 
maximum number of ten trials were performed until minimal deviation of the signal was 
reached. The data was fitted according to a one site binding model by least square fitting 
using the Origin data analysis software: 
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where ΔA is the measured anisotropy difference, x the applied protein concentration and Kd 
the deduced dissociation constant.  
2.2.5.3 Dot Blot Double Filter Binding Assays 
MDA5 binding to poly I:C was measured by filter binding assays on a double layer of 
nitrocellulose and nylon filters (Manzan et al. 2004). Prior to filtration, the nitrocellulose filter 
was activated by soaking it in 0.4 M KOH for 10 min followed by extensive rinsing with water. 
Both membranes were subsequently equilibrated in assay buffer (20 mM Tris pH 7.5, 150 
mM NaCl, 10 µM ZnCl2, 1mM DTT) for 10 min. Poly I:C (Sigma, Deisenhofen, Germany) was 
5´ 32P labeled by T4 Polynucleotide kinase (MBI Fermentas) according to the manufacturer’s 
instructions. A concentration series ranging from 0 μM to 5 μM protein was incubated with 50 
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nM poly I:C for 20 min at 4°C and then filtered through a double layer of a nitrocellulose filter 
(PROTRAN BA85, Schleicher & Schuell) and a nylon filter (Roti-Nylon plus, Roth; 
nitrocellulose on top of nylon membrane) in a 96 well dot blot apparatus (Schleicher & 
Schuell). Proteins and protein poly I:C complexes bind to the nitrocellulose filter, while the 
remaining free oligonucleotides bind to the nylon filter allowing complete recovery of labeled 
poly I.C. For quantification the radioactivity was recorded using a STORM Phosphorimager 
system (Amersham). The ratio of protein-bound to unbound RNA was determined using 
Image Quant software.  
2.2.6 Peptide SPOT Protein-Peptide Interaction Assay 
Overlapping MDA5 peptides of 12 amino acids in length were synthesized on a nitrocellulose 
membrane in an array of spots with an offset of 2 amino acids using an automatic MultiPep 
synthesis robot (Intavis, Cologne, Germany) following the manufacturer’s instructions. Two 
identical peptide arrays covering the full-length MDA5 protein were synthesized in parallel. 
Potential V-protein MDA5 peptide interactions were assayed by Far Western blotting. All 
buffers and their components used for Far Western blotting are listed in Table 9. After SPOT 
synthesis, the nitrocellulose membrane was washed three times with TBS-T and then 
blocked for 2-3 h with TBS-T Milk. Myc-tagged GST-V-protein or alternatively control protein 
(myc-GST, kindly provided by Natalie Hiller) was added to the blocking solution (final 
concentration 1 µM) and incubated at 4°C overnight shaking. The membrane was 
consecutively washed with TBS-T, TBS-T NaCl, TBS-T Triton, and again TBS-T for 5 min 
shaking. The membrane was then incubated with the primary myc specific antibody (Myc A-
14 sc-789, rabbit, Santa Cruz Biotechnology, Santa Cruz, USA) diluted 1:2000 in TBS-T Milk 
and subsequently washed as described before. After incubation with the secondary antibody 
(Peroxidase AffiniPure Goat Anti-Rabbit IgG, Jackson ImmunoResearch, Suffolk, UK) in a 
1:5000 dilution and similar washing procedures, the membrane was developed using ECL 
Western Blotting Detection Reagent (GE Healthcare, Freiburg, Germany) following the 
manufacturer’s instructions. Detection of luminescent signal was performed on a 
Luminescence Image Analyzer LAS-3000 (Fuji Film, Woodbridge, USA). 
Table 9: Buffers used for Far Western detection 
Buffer Composition 
TBS-T 20 mM Tris pH 7.6, 140 mM NaCl, 0,1 % (v/v) Tween 20 
TBS-T NaCl (20 mM Tris pH 7.6, 500 mM NaCl, 0,1 % (v/v) Tween 20) 
TBS-T Triton TBS-T + 0.5% (v/v) Triton X-100 
TBS-T Milk TBS-T + 5% (w/v) milk powder 
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2.2.7 Structure Determination by Small Angle X-Ray Scattering 
Small angle X-ray scattering allows gathering of structural information of proteins and other 
biomolecules without the need for high ordered crystals as needed for X-ray crystallography. 
The method has the advantage of making flexible parts of the protein, which usually hinder 
crystallization, accessible for structural analysis. Furthermore, SAXS measurements of 
protein samples are performed in solution, thus closer reflecting the natural conditions in 
which proteins occur in vivo. SAXS data can be used to calculate an ab intio protein model. 
However, the structures obtained are of relatively low resolution (maximum 15Å) and the 
obtained solutions for shape reconstructions are not always unambiguously interpretable. 
Comparison with existing high resolution data such as partial crystal structures is therefore 
advisable to further evaluate the obtained model. Through this combination with X-ray 
crystallography, SAXS is a powerful tool which may provide more accurate and complete 
models of protein structures, conformation, interactions and assemblies in solution (Putnam 
et al. 2007). 
In a SAXS experiment the X-ray wave is scattered mainly by the electrons surrounding the 
atoms of the examined biomolecule (protein). As the contribution of the solvent scattering is 
relatively high, SAXS experiments on proteins require separate measurements of the 
scattering from sample and solvent. As SAXS is performed in solution, the proteins are 
spatially averaged and no diffraction pattern can be observed. Instead the scattering image is 
recorded as a function of the momentum transfer )sin(4 1 θπλ−=s  where 2θ  is the scattering 
angle. At the lowest resolution, SAXS scattering is dictated by a single size parameter, the 
radius of gyration (RG). The RG is the square root of the average squared distances of each 
scatterer from the center of the particle that is scattering X-rays and therefore a measure for 
the size of the particle. For well-behaved samples with no interparticle interference or 
aggregation the scattering can be related by the Guinier approximation, 
( ) 22310 sRGeIsI −≅  
where I0 is the intensity at the scattering amplitude s = 0. The Guinier plot, where ln (I(s)) is 
plotted versus s2 should give a linear function with I0 as intercept and a slope that can be 
used to calculate RG. Only very homogenous samples with low intermolecular attractive 
forces will give a linear Guinier plot. Therefore, it is also a useful tool to test sample quality. 
Whereas analysis of low s-values gives information about the particle dimension, analysis of 
high s-values yields details regarding the molecular shape. For a folded macromolecule the 
intensity of the scattering falls off with Porod’s law: 4)( −∝ ssI  
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The Kratky plot (s2I(s) as a function of s, which is deduced from the Porods’s law and which 
can be calculated directly from the scattering curve, provides an excellent tool for evaluating 
the folding status of samples. For folded domains, which have intensities that fall off as s-4, 
the Kratky plot yields a peak roughly shaped like a parabola. Unfolded peptides lack the 
characteristic folded peak and are linear with respect to s in the large s region. 
 
Figure 5: The Kratky plot gives information about protein folding. 
Globular macromolecules have bell-shaped curves. Unfolded proteins lack this peak and have a plateau in the 
larger s range. Adapted from Putman et al 2007. 
After the quality of the protein sample has been critically assessed, the the scattering profile 
I(s) is fourier transformed into the pair distribution function (Figure 19) according to the 
following equation: 
( ) ( ) dr
sr
srsIsrrp sin
2 0
2
2
2 ∫∞= π  
The pair distribution function can be understood as a two-dimensional Patterson function that 
illustrates the frequency with which vectors of the length r connect two volume elements 
within the molecule. The pair distribution function is a real space representation and therefore 
much more intuitive than the primary scattering curve. The shape of the pair distribution 
function provides information about the shape of the molecule. Theoretically, the p(r) is zero 
at r = 0 and at r ≥ Dmax, where Dmax corresponds to the maximum linear dimension of the 
scattering particle. Dmax cannot be directly calculated from the scattering data but must be 
estimated for a given molecule. In practice an iterative process is used, with multiple Dmax 
values chosen and the resulting p(r) functions evaluated for their fit to the experimental data. 
As described above, several sample parameters can be derived in a straightforward manner 
directly from the scattering data. In a computationally more demanding step the three-
dimensional reconstruction of the particle from the two-dimensional scattering curve is also 
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feasible. Fitting the data leads to a multidimensional minimization problem that can be 
however numerically solved. To achieve reasonable models it is helpful to add physical 
restraints, like imposing a uniform density on the interior of the molecule. The program 
GASBOR models a protein structure by comparing thousands of configurations of a chain of 
dummy residues where each dummy correspond to a single amino acid in the protein of 
interest (Konarev et al. 2006). The structure is approximated by iterative rounds of simulated 
annealing with additional penalties for non-protein-like density. To improve model quality the 
results of several individual GASBOR runs should then be aligned and averaged for a final 
shape. Through comparison of different models and assessment of their capability, an 
evaluation of the reliability of the final model is possible. In a perfect monodisperse system all 
runs should converge on a similar structure.  
2.2.7.1 Sample Preparation 
MDA5-RD samples were purified as described (see chapter 2.2.4.2). The final gel filtration 
buffer contained 5 mM DTT in order to reduce radiation damage. The purified protein was 
concentrated using centrifugal devices (Amicon® Ultra, Millipore, Billerica, USA) and aliquots 
were taken at 2, 5 and 10 mg/ml. A sufficient volume of gel filtration buffer from the same 
preparation used for the final purification step was stored for reference measurements  
(Table 7). 
2.2.7.2 Sample Measurement 
MDA5-RD samples were measured at the DESY beamline X33 (Deutsches Elektronen-
Synchrotron Hamburg, Germany). All measurements were performed at room temperature 
after centrifugation in a cooling centrifuge. As a primary quality check, samples were 
analyzed for protein aggregation by calculating the Guinier plot using the PRIMUS software 
(Konarev et al. 2006). To evaluate possible radiation damage, MDA5-RD was subjected to 
three consecutive exposures of different length (6 seconds, 60 seconds and 6 seconds). 
During the following data acquisition, MDA5-RD samples were measured at increasing 
protein concentrations. A blank measurement with sample buffer was taken before and after 
each protein measurement. 
2.2.7.3 Data Analysis and Ab Initio Modeling 
Initial analysis of the primary scattering data was performed using the PRIMUS software 
package (Konarev et al. 2006). Scattering contributions of buffer were eliminated by 
subtracting the averaged blank measurements. The protein scattering intensity was scaled 
according to the respective concentration and subsequently merged in one dataset. The 
radius of gyration (RG) was calculated using the linear region Guinier plot. Correct folding of 
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the protein was evaluated in the Kratky plot. During iterative improvement of the pair 
distribution function (p(r)) using the program GNOM the correct maximum particle diameter 
(Dmax) was estimated by evaluating the resulting RG value, the I(s)-fit and the shape of the 
p(r)-distribution. Ab initio modeling of the MDA5-RD solution structure was done with 
GASBORp (Svergun et al., 2001). More than 10 identically calculated models were aligned 
and averaged using DAMAVER and SUPCOMB (Konarev et al. 2006). 
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3 Results 
3.1 Structure Guided Mutagenesis of the RIG-I 
Regulatory Domain and RNA Binding Studies 
Through a limited proteolysis approach our laboratory identified a stable part of the C-
terminal RD of RIG-I. This was amenable to crystallization and its three dimensional structure 
was determined by X-ray crystallography. Preliminary results from Sheng Cui hinted to a 
potential role of RD in recognition of the 5’-triphosphate motif of viral RNA. Analysis of the 
electrostatic surface potential indicated a positively charged patch on the concave side of RD 
which might be important for RNA recognition. Since RIG-I RD resisted crystallization with 
RNA ligands, structure-guided mutagenesis was performed on several basic residues within 
the positively charged cleft to reveal the influence of the individual mutations on RNA binding. 
The mutants were subsequently used for RNA binding studies and their binding capabilities 
were compared to that of RIG-I RD wild type protein. 
The electrostatic potential of RIG-RD was calculated using the APBS plugin for PyMol 
(Figure 6). Primarily, basic residues in the center of the positively charged pocket were 
targeted for site specific mutagenesis. In addition, two control residues located on the convex 
side of RIG-I RD, and therefore should not affect RNA binding, were also targeted. The 
respective residues (K858, K888, I875, H830, D836, K807 and I875) were all mutated to 
alanine.  
 
Figure 6: Analysis of the RIG-I RD crystal structure and introduced mutations. 
Electrostatic surface potential (ranging from blue = 9 kT/e to red = -9 kT/e), displayed in two different views. 
Sites of mutated residues are annotated.  
Subsequently, the six mutants were expressed and purified in parallel (Figure 7) using the 
previously established protein production protocols for the RIG-I RD wildtype (Cui et al. 
2008). Expression of all mutants resulted in yields comparable to the wild type construct. 
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Figure 7: Expression and purification of RIG-I RD mutants. 
SDS-PAGE analysis and Coomassie staining of RIG-I RD mutants after purification. Molecular weight standard 
(MWS) with respective sizes and respective mutations are annotated.  
The RNA binding affinities of the indicated RIG-I RD mutants were determined and compared 
to RD WT and RIG-I full length protein using a fluorescence anisotropy assay. For this, the 
RNA was fluorescently labeled by incorporating Alexa Fluor 488-UTP into the RVL sequence 
during the in vitro transcription reaction. Titration of increasing amounts of protein into a 
constant concentration (50 nM) of fluorescent pppRVL, resulted in a measurable anisotropy 
change (Figure 8). The data was fitted according to a one site binding model and 
dissociation constants (Kd) were calculated by least square fitting. 
Clearly, the RIG-I WT (full-length) protein showed the highest affinity (Table 10). However, 
most of its binding capacity to pppRVL resided within the RD, as this by itself had an only 
slightly elevated Kd in comparison to the full-length protein. Mutations in the positively 
charged groove of RD had a significant impact on pppRVL binding. The K858A mutation 
almost completely abolished RNA binding. Importantly, the control mutations outside the 
postulated binding site did not affect the affinity to pppRVL. In summary, these results clearly 
identified the positively charged cleft within the RIG-RD domain as the binding site for the 5’-
triphosphate motif. 
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Figure 8: Impact of introduced mutations in RIG-I RD on RNA binding affinity 
Fluorescence anisotropy changes (ΔAnisotropy) of fluorescently labeled pppRVL in response to titration with 
WT RD and the indicated RD mutants, respectively. 
Table 10: RIG-I RNA binding affinities 
No mutations  
RIG-I WT (full-length) Kd = 151 ± 8 nM 
RIG-I RD Kd = 217 ± 18 nM 
  
Mutations inside  the positive charged groove  
RD K858A Kd > 5,000 nM 
RD K888A Kd = 1,003 ± 180 nM 
RD I875A Kd = 1,012 ± 109 nM 
RD H830A Kd = 495 ± 34 nM 
  
Control mutations on the convex side  
RD D836A Kd = 185 ± 15 nM 
RD K807A Kd = 254 ± 16 nM 
  
 
3.2 Functional Dissection of the Individual RIG-I 
Domains 
The RD comprises only a very small part of the RIG-I full length protein. In addition, RIG-I 
harbors tandem CARDs and a central helicase domain (Figure 9A). Importantly, intact RIG-I 
ATPase activity is crucial for RIG-I mediated antiviral signaling (Gack et al. 2008). To 
investigate the importance and functional contribution of RD in the context of the full-length 
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protein, ATPase assays were performed with the complete RIG-I protein and several RIG-I 
truncation variants lacking either RD and CARDs or both domains.  
To this end, several RIG-I truncation mutants were purified according to established protocols 
(Cui et al. 2008). The RIG-I-ΔRD construct was provided by Sheng Cui. The purified RIG-I 
constructs (Figure 9B) were then used in biochemical ATPase assays, RNA binding studies 
and single molecule translocation experiments. 
 
Figure 9: RIG-I constructs used in functional studies. 
(A) Schematic representation of constructs used. Domains and domain borders are annotated. RIG-I SV lacks 
amino acid 36-80 (black triangle) in the first CARD (C1). (B) Coomassie gel showing the final purity of selected 
constructs and molecular weight standards (MWS) are shown as annotated.  
Catalytic efficiencies were determined (kcat/KM) by measurement of the initial reaction velocity 
at increasing ATP concentrations. As exemplarily shown for the RIG-I-ΔCARD construct, the 
reaction mixtures were separated by thin layer chromatography and visualized using trace 
amounts of γ-32-P-ATP (Figure 10). Two types of RNA were used for stimulation: in vitro 
transcribend pppRVL and synthetic dsRNA without modification at the termini. 
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Figure 10: Determination of catalytic efficiency (kcat/KM) of the RIG-I-ΔCARD construct. 
(A) Thin layer chromatography of ATPase reactions for a representative RIG-I construct (in this case RIG-I-
ΔCARD) at 50 µM RVL RNA concentratiosn and decreasing ATP concentrations. (B) ATPase hydrolysis was 
quantified and initial reaction velocities determined by phosphor imaging. (C) Plotting of these initial velocities 
against ATP concentration revealed Michaelis-Menten kinetics and allowed determination of the catalytic 
efficiencies by least square fitting.  
A comparison of the catalytic efficiencies revealed that RIG-WT protein was best stimulated 
by pppRVL. Only very poor ATPase activity was detected with non-phosphorylated dsRNA 
(Figure 11A). The ΔCARD-RIG-I construct showed a similar ATPase activity as the WT 
protein but, remarkably, had lost its preference for pppRVL with dsRNA also being an equally 
good stimulator. In comparison to the full length protein, removal of the CARDs seemed to 
relieve an inhibitory effect on the dsRNA-induced ATPase activity. The isolated helicase 
domain retained a residual activity, however dsRNA could activate its ATPase activity more 
efficiently than pppRVL. RIG-I-ΔRD showed no ATPase activity. Therefore, a functional RD 
seems to be essential for RIG-I catalytic activity. 
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Figure 11: Comparison of ATPase activities of RIG-I variants and dose dependent 
inhibition by RD. 
(A) RIG-I WT and truncation variants were stimulated with pppRVL (black bars) or non-phosphorylated dsRNA 
(white bars). Error bars represent standard deviations of the non linear regression analysis of catalytic 
efficiencies (kcat/KM). (B) Inhibition of the intial ATPase velocity (v) of 20 nM RIG-I-ΔCARD by adding indicated 
amounts of RD in the presence of 200 nM pppRVL (white bars) or 200 nM dsRNA (black bars). Data shown in 
A and B represent means and standard deviations (error bars) of three independent experiments. 
It has been previously demonstrated that overexpression of RD inhibits RIG-I signaling (Saito 
et al. 2007). Knowing that RD strongly binds to 5’-triphosphate ends of single stranded RNA, 
it was hypothesized that the inhibitory effect seen on interferon production might be due to 
competition of RD with full-length RIG-I for the stimulatory RNA. RD would efficiently mask 
5’-triphosphate ends in a way that the full-length protein can no longer be activated. To test 
this idea, increasing amounts of RD were titrated into a reaction mixture containing ΔCARD-
RIG-I (Figure 11B). Whereas RIG-I-ΔCARD in the absence of additional RD was equally well 
stimulated by pppRVL and dsRNA, increasing amounts of RD indeed inhibited pppRVL-
stimulated RIG-I ATPase activity in a dose dependent manner. In contrast, dsRNA-induced 
activation of RIG-I was not significantly affected. Importantly, these results complement the 
published in vivo data and confirm our competition hypothesis. Moreover, these results 
independently corroborate the conclusion drawn from the direct binding assay (Figure 8), 
that is the potent and specific binding of 5’-triphosphate RNA to the RIG-I RD.  
In addition to the functional studies with RIG-I truncation variants, the ATPase activity and 
RNA binding capacity of the RIG-I splice variant (SV) was also analyzed. This protein carries 
a deletion within the first CARD (Δ36-80) and thereby loses its downstream signaling ability 
due to a failure to interact with the ubiquitin ligase TRIM25 (Gack et al. 2008). Importantly, 
RIG-I SV acts in a dominant negative manner on the RIG-I-mediated antiviral interferon 
response. However, the molecular mechanism of inhibition is unclear. One possible 
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explanation would be the sequestration of viral RNA. However, to be able to compete for viral 
RNA ligands, the binding ability of RIG-I SV to 5’-triphosphate RNA must still be intact. 
Another intriguing question is if the amino acid deletion within the first CARD has any 
influence on the ATPase acitivity of RIG-I SV. As described above, a similar effect was 
observed for the RIG-I-ΔCARD construct.  
Detailed biochemical analysis showed that indeed RIG-I SV ATPase activity was stimulated 
by pppRVL, as well as dsRNA in the same order of magnitude as RIG-I WT (Figure 13A). 
Importantly, both proteins show a similar affinity (RIG-I WT Kd = 246 nM; RIG-I SV Kd = 233 
nM) to pppRVL as determined by fluorescence anisotropy (Figure 13B). These data suggest 
that RIG-I SV inhibits interferon signaling by sequestering viral RNA into signaling-
incompetent protein complexes. Notably, RIG-I SV retains a preference for pppRVL over 
dsRNA. This suggests that despite being truncated, the CARDs still exert an inhibitory 
influence on the ATPase-activation by dsRNA. 
 
Figure 12: ATPase activity and RNA affinity of the RIG-SV in comparison to RIG-I WT.  
(A) RIG-I WT and RIG-I SV were stimulated with pppRVL (black bars) and non-phosphorylated dsRNA (white 
bars). The ATPase efficiency (kcat/KM) of RIG-SV is in a similar range as the one of RIG-I WT. (B) Fluorescence 
anisotropy changes (ΔAnisotropy) of fluorescently labeled pppRVL in response to titration with RIG-I WT (open 
circles, Kd = 246 ± 42 nM) and RIG-I SV (filled square Kd = 233 ± 35 nM). The deletion in RIG-I SV does not 
seem to affect RNA binding. 
Next, it was investigated if RIG-I, which harbors a helicase motif, was able to translocate 
along an RNA double-strand in an ATP dependent manner. Since protein dynamics are 
difficult to follow with classical biochemical methods, RIG-I variants were tested in a setup 
allowing the tracing of moving single molecules (Figure 9). These experiments were 
performed by the group Prof. Taekjip Ha which was provided with purified RIG-I protein 
constructs. 
32 Results 
 
Figure 13: RIG-I shows translocation activity in a single-molecule setup. 
(A) A 25mer dsRNA fluorescently labeled with DY547 was immobilized via a biotin modification to a 
streptavidin-coated matrix (illustrated in the left panel). Addition of RIG-I-WT and ATP leads to a repetitive 
association with (fluorescence increase) and dissociation from (fluorescence decrease) a single RNA molecule 
(middle panel). The dwell time (Xc) calculated by Gaussian fitting of all Δt values allows calculation of a 
translocation velocity (1/ Xc). (B, C) Similar setups as described in (A) using the ΔCARD-RIG-I construct 
instead of RIG-WT (B) and a dsRNA with a single stranded extension and a 5’-triphosphate modification (C), 
respectively. Adapted from (Myong et al. 2009). 
RIG-I WT protein showed a robust, ATP-dependent translocation activity on dsRNA (Figure 
13). Translocation in this context is defined as a movement along the axis of the RNA double 
strand. By employing a newly developed method, Protein Induced Fluorescence 
Enhancement (PIFE), protein dynamics could be followed without a fluorescent label on the 
protein. PIFE relies on the spectral properties of the DY547 dye, which emits fluorescence 
signals corresponding to the proximity of the unlabeled protein. Two types of immobilized 
RNA were used for RIG-I stimulation; either an RNA duplex of 25 bp or a 20mer duplex with 
a single stranded 5’-overhang plus a triphosphate modification (Figure 13A, C; left panels). 
The velocity of translocation was determined by calculating the average time interval 
between successive intensity peaks (Xc): the shorter the time interval, the higher the 
enzymatic function. Notably, the translocation activity of RIG-I was much more rapid in the 
presence of 5’-triphosphate (xc = 0.85 s) in comparison to blunt-ended dsRNA (18.5 s). In 
accordance with our ATPase studies (Figure 11), RIG-I-ΔCARD was again much more active 
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on unmodified dsRNA (xc = 1.1 s) than RIG-I WT (xc = 18.5 s) (Figure 13A, B). This finding 
further supports a model in which the CARDs exert an inhibitory effect on the helicase 
(ATPase) domain. Intriguingly, the inhibition by the CARDs could be relieved by the presence 
of a 5’-triphosphate modification of the RNA ligand (Figure 13 C). It is also noteworthy, that 
RIG-I apparently needs the combination of both molecular patterns to reach full enzymatic 
activity; a single stranded RNA with 5’-triphosphate ends and dsRNA portions. 
3.3 Functional Analysis of MDA5 and Its Interaction 
with Paramyxovirus V-Protein 
MDA5 and RIG-I both act as cytosolic receptors for viral RNA. However, they recognize 
different types of viral RNA. Whereas RIG-I-dependent interferon signaling is specifically 
induced by 5’-triphosphate RNA and short dsRNA, MDA5 signaling is specifically inducible by 
poly I:C (Hornung et al. 2006; Kato et al. 2006; Pichlmair et al. 2006). poly I:C is a hybridized 
complex of a poly inosine (I) and a poly cytosine (C) strand, and is thought to mimic dsRNA. 
Despite extensive research on RLRs over the past five years, the physiological ligand 
recognized by MDA5 remains undefined. It had previously been shown that the length of 
dsRNA might be an important criterion (Saito and Gale 2008). 
To identify the physiological MDA5 ligand, a MDA5 ATPase assay in accordance to the RIG-I 
functional test was established. In this new setting poly I:C was used as the positive control. 
The utilized protein constructs and their final purity are shown in Figure 14A and B. Indeed, 
poly I:C is able to stimulate MDA5 ATPase activity in vitro (Figure 14C). Interestingly, MDA5-
Δ-CARD has a higher ATPase activity than MDA5 FL. This finding is reminiscent of the 
functional properties of RIG-I where the FL is also less active than the RIG-I-ΔCARD 
construct when stimulated with dsRNA (chapter 3.2). Therefore, in both cases the CARDs 
seem to have an inhibitory effect on ATPase activity. 
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Figure 14: MDA5 ATPase stimulation by various RNA structures. 
(A) Domain architecture of MDA5 constructs utilized in functional and structural studies. Domains are colored 
by the scheme as indicated at top. Terminal amino acid positions are numbered. (B) SDS-PAGE analysis using 
Coomassie staining of MDA5 FL and MDA5-ΔCARD. Final purified protein as used for ATPase assays with 
molecular weight standard (MWS) annotated. (C) RNA sequences used to stimulate MDA5 ATPase activity. (D) 
MDA5 FL and MDA5-ΔCARD (concentration 100 nM) were stimulated by 50 nM of the respective nucleic acid 
in the presence of 100 µM ATP. Initial reaction velocities (v) were determined by thin layer chromatography and 
phosphorimaging as described for Figure 10.  
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Furthermore several potential MDA5 ligands were tested for their ability to activate the 
MDA5-ATPase (Figure 14C, D). Since MDA5-ΔCARD could be purified more easily and 
showed higher activity in initial tests, this construct was used preferentially during the 
following analysis. MDA5 activation is absolutely dependent on double stranded 
oligonucleotides, since single-stranded poly I and poly C alone could not activate MDA5 
significantly. Additionally a single stranded RNA with a 3’-monophosphate (3’P), which had 
been described as a potent RIG-I activator (Malathi et al. 2007), also failed to induce MDA5 
activity. Notably, the length of the double strand seems to be an important criterion, since a 
chemically synthesized oligonucleotide with a high I:C content and a length of 25 bp (short 
I:C) was less stimulatory than poly I:C (a heterogeneous mixture of polynucleotides with a 
length >2000 bp). Interestingly, the sequence and the resulting structural features of the RNA 
seem to play an important role in its capability to stimulate MDA5. Synthetic dsRNA built from 
the rabies virus leader sequence paired to its complementary strand (length 50 base pairs) 
was less stimulatory than short I:C. Furthermore, when introducing an I:U mismatch into the 
short I:C double stranded oligonucleotide, its ability to induce MDA5 ATPase activity was 
significantly reduced. 
 
Figure 15: MDA5 ATPase activity is inhibited by increasing amounts of V-protein. 
(A) MDA5 and V-protein complex co-purified by gelfiltration chromatography. SDS-Page analysis and 
Coomassie staining of MDA5 FL (~120 kDa) and an N-terminally truncated version of Measles Virus V-protein 
(residues 49 – 299, ~30 kDa). (B) MDA5 ATPase activity is inhibited by V-protein in a dose-dependent manner. 
MDA5-CARD (100 nM) was stimulated by 50 nM poly I:C in the presence of 100 µM ATP and increasing 
amounts of Measles Virus V-protein. For each reaction initial ATPase reaction velocities (v) were determined. 
Paramyxovirus V-proteins interfere with MDA5-dependent signaling by binding to MDA5 via a 
conserved cysteine-rich C-terminus, thereby inhibiting its function (Andrejeva et al. 2004; 
Childs et al. 2007). It was tested whether the detrimental interaction found in vivo could also 
be reconstituted in vitro. Indeed, when co-expressed, full length as well as N-terminally 
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truncated Measles Virus and Simian Virus 5 (SV5) V-protein with a MDA5 FL could be co-
purified (Figure 15A).  
The structural and mechanistic details of the MDA5 V-protein interaction are still poorly 
understood, including which domains within MDA5 are targeted, and whether the ATPase 
activity, essential for downstream signaling is affected by V-protein binding. These questions 
were addressed by performing the previously described MDA5 ATPase assay (Figure 15B). 
Increasing amounts of purified Measles Virus V-protein (residues 49 – 299) were titrated to 
poly I:C stimulated MDA5-ΔCARD. Increasing amounts of V-protein were found to inhibit the 
ATPase reaction in a dose-dependent manner. At a saturating concentration of V-protein (1 
μM), less then 5% residual MDA5 activity was observed. 
Since V-protein seems to interfere directly with MDA5 ATPase activity it is speculated that its 
inhibition is due to a direct targeting of the helicase (DECH box) motifs. In a primary unbiased 
approach, the regions of MDA5 that internact with V-protein were mapped using a peptide 
interaction scan. Overlapping, MDA5-derived peptides of 12 amino acids length were probed 
for interaction with myc-tagged SV5 V-protein (Figure 16A). The peptide array has the 
advantage of covering the entire polypeptide in fine resolution. However, only linear epitopes 
can be recognized, while epitopes present only in the tertiary structure cannot be 
reconstituted on the array. Additionally, regions of the protein that are normally buried in the 
hydrophobic core might be exposed and cause false positive interactions. Therefore protein 
interactions indicated by this assay need to be confirmed by further independent 
experiments. Nevertheless, the peptide screen yielded interesting results. Interacting 
peptides were found within both the N-terminal, as well as within the C-terminal RecA fold of 
the MDA5 helicase domain, suggesting that V-protein indeed binds to the DECH box domain 
(Figure 16B). Surprisingly additionally interacting peptides were also found within the first 
CARD as well as within the C-terminal RD. However, as these results could not be confirmed 
by in vitro interaction studies with purified protein components (data not shown), they 
probably represent experimental artifacts. 
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Figure 16: A Peptide SPOT assay reveals multiple V-protein MDA5 interaction sites. 
(A) A MDA5 peptide-array was probed with V-protein or a negative control protein (myc-GST). Non-specific 
interactions in the control blot (right panel) allow the identification of specific MDA5 / V-protein interactions 
(MDA5 amino acid positions annotated). (B) The interaction sites (grey stars) were mapped on the MDA5 
sequence. (C) SDS-PAGE analysis and Coomassie staining of co-purified MDA5 V-protein complex. GST 
tagged V-protein (GST-SV5V) remains bound to His tagged MDA5 N-terminal RecA domain (His6-MDA5 287-
499) after a tandem affinity purification with Ni-NTA followed by purification with GST-sepharose. Molecular 
weight standard (MWS) with respective sizes and respective fractions during purification are annotated. 
By co-expressing a series of truncation variants of the MDA5 helicase domain the MDA5 V-
protein interaction site was further narrowed to the N-terminal Rec A domain of MDA5, which 
harbors the critical helicase motifs I, Ia, II, III (Figure 14A). The N-terminal RecA fragment 
(MDA5 297-499) co-purified with V-protein during dual affinity purification (Figure 16C) and 
was therefore sufficient for V-protein binding. Although a stable homogenous complex could 
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be purified, further structural analysis by X-ray crystallography was hindered by the relatively 
high instability of the V-protein constructs. 
 
Figure 17: V-protein does not influence binding affinity of poly I:C to MDA5. 
(A) Affinities of 32P-labeled poly I:C were determined by dot blot filter binding assays. Increasing protein 
concentrations were incubated with 50 µM poly I:C. MDA5 FL was inhibited with an excess of 5 µM V-protein. 
(B) The blots were quantified by phosphorimaging. V-protein neither sequesters poly I:C directly (open 
squares), nor does it inhibit binding of MDA5 to poly I:C (open circles and dashed black line MDA5 FL alone; 
up facing triangles and solid black line MDA5 FL + 5 µM V-protein). 
To learn more about the mechanism of inhibition, the binding of V-protein to MDA5 was 
tested to see if access of RNA to the helicase domain could be blocked. The affinity of poly 
I:C to MDA5 was measured in the presence and absence of an inhibiting amount of V-protein 
by utilizing a dot blot filter binding assay (Figure 17). Poly I:C binding to MDA5 was not 
affected by the addition of V-protein. Importantly, V-protein alone was incapable of binding to 
poly I:C thereby excluding the possibility of inhibition by substrate sequestration. Thus, 
competition with nucleic acid binding is not the mechanism of inhibition of ATPase activity of 
MDA5 by V-proteins. It is also of note that the binding affinity to poly I:C seems to primarily 
reside within the helicase domain, since deletion of the CARD domain does not reduce poly 
I:C affinity and the isolated RD shows only very low binding. 
3.4 Structural Studies on the MDA5 Regulatory Domain 
with Small Angle X-Ray Scattering and Homology 
Modeling 
Our laboratory successfully determined the X-ray structures of the C-terminal RDs of both 
RIG-I and LGP2 (Cui et al. 2008; Pippig et al. 2009). Clearly, a structural comparison 
between these structures and the MDA5 RD would be highly informative. However, despite 
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extensive effort, MDA5 RD resisted crystallization. As an alternative to X-ray crystallography, 
analysis by small angle X-ray scattering (SAXS) in combination with molecular modeling can 
provide structural envelope, to allow comparison to the MDA5, RIG-I and LGP2 RDs. 
To structurally characterize MDA5 RD a series of MDA5 constructs were cloned and purified 
from three different species (human, mouse and chicken). Figure 18 demonstrates the final 
purity of the human construct 897-1025. 
 
Figure 18: Purification of MDA5 RD. 
SDS-PAGE analysis of the MDA5 construct 897-1025 after final gel filtration purification step. Molecular weight 
standard (MWS) with respective sizes and respective fractions during purification are annotated. 
This construct was subsequently analyzed in solution by small angle X-ray scattering 
(SAXS). The measurements were performed at three different protein concentrations (2, 5 
and 10 mg/ml) and the resulting spectra merged after appropriate scaling using the data 
analysis software package ATSAS (Konarev et al. 2006). After ten individual rounds of ab 
intio modeling with GASBORp the models were manually oriented and averaged resulting in 
the final envelope shown in Figure 19B. SAXS analysis of the RIG-I RD was performed by 
Sheng Cui and the data provided for a comparison with MDA5 RD data. 
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Figure 19: Small angle X-ray scattering analysis and molecular modeling of MDA5 RD. 
(A) Primary scattering curves (upper panel) and calculated pair distribution functions (lower panel) of MDA5 
and RIG-I RD (colored as indicated). (B) Ab initio molecular envelopes (faint gray; RIG-I RD right panel; MDA5 
RD left panel) calculated from the primary data as shown in (A) and superimposed with the RIG-I RD crystal 
structure (yellow) and an MDA5 model (blue). The theoretical model for MDA5 RD matches the experimentally 
determined SAXS envelope. (C) Comparison of the electrostatic surface potential of MDA5 and RIG-I RD. Both 
domains harbor a similar positively charged patch, however residues which have been shown to be essential 
for the RNA-binding capability of RIG-I are not conserved in MDA5 (e.g. K858RIG-I in comparison to I956MDA5). 
As already obvious from the primary scattering curves and the calculated pair distribution 
function (Figure 19A) the solution structures of RIG-I RD and MDA5 RD are very similar in 
dimension. Accordingly, the obtained radii of gyration (RG) are almost identical (RG RIG-I-RD = 
16.2 Å and RG MDA5-RD = 16.1 Å). Furthermore, the calculated envelope of MDA5 correlates 
very well with the geometry of the RIG-I RD SAXS model and the corresponding crystal 
structure (Figure 19B; left panel). The high conservation of hydrophobic core regions and 
important structural motifs, such as zinc-coordinating cysteines (Figure 20) is also very 
conspicuous. Taken together these observations suggest that the RIG-I and MDA5 RDs 
posses an overall similar structure. To obtain deeper molecular insights into the MDA5 RD 
structure, the program MODELLER was employed to calculate an initial model of the MDA5-
RD structure. For this, a sequence alignment of MDA5 RD with the respective domains of 
RIG-I and LGP2 plus the RIG-I and LGP2 RD crystal structures were used as input. It is likely 
that the model will differ in precise orientation of flexible loop regions from a respective high 
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resolution structure. Nevertheless, the calculated model fit the experimentally determined 
SAXS envelope well (Figure 19B; right panel). Interestingly, MDA5 RD shows a similar, 
positively charged patch as was found in RIG-I RD (Figure 19C). This is surprising, because 
in contrast to RIG-I RD and LGP2 RD, the binding affinity of MDA5 RD to RNA is very low. 
No binding to poly I:C (Figure 17) or to pppRVL could be detected (Cui et al. 2008). As 
expected from this observation, the critical residues mediating the RNA interaction in RIG-I 
are not conserved in MDA5 (i.e. K858RIG-I in comparison to I956MDA5, Figure 19C). 
 
Figure 20: Structure-based sequence alignment of RLR-RDs. 
Conserved residues in MDA5, RIG-I and LGP2 RDs are highlighted in red boxes and red letters. The 
secondary structure for MDA5 as predicted by MODELLER is depicted on top. Residues important for folding 
such as the zinc-coordinating cysteines and hydrophobic core residues are marked by a red asterisk.  
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4 Discussion 
4.1 The Positively Charged Patch within RIG-I RD is the 
Recognition Site for 5’-Triphosphate RNA 
The C-terminal RD domain of RIG-I is key to the recognition of viral PAMPs. Through 
structure-guided mutagenesis, it was shown that the positively charged patch, identified in 
the RIG-I RD crystal structure, is indeed the 5’-triphosphate recognition site in RIG-I. 
Mutating of several residues within the binding pocket severely reduce the binding affinity to 
pppRVL. An especially drastic effect is seen when K858 is mutated to alanine, indicating that 
this residue is central for RNA binding. This particular lysine is situated in the center of the 
positively charged binding pocket and its location is therefore well suited for phosphate 
interaction. Interestingly, in LGP2 and MDA5 this side chain is not conserved, being either a 
proline and or an isoleucine (Figure 20), which might explain the observed differences in 
ligand specificity between the three helicases. RIG-I RD specifically binds to pppRVL and 
LGP2 prefers dsRNA (Cui et al. 2008; Pippig et al. 2009), whereas MDA5 shows a 
comparably low affinity to all kinds of RNA tested. 
 
Figure 21: Overlay of the LGP2 RD RNA complex with Rig-I RD. 
Superposition (ribbon presentation) of the LGP2 RD (in grey) plus RNA (orange, red and blue) and the RIG-I 
RD (in yellow). Crucial residues for recognition of the 5’-triphosphate motif within RIG-I are shown as sticks 
with annotated site chains. The termini of the RNA oligonucleotide are labeled accordingly. 
A recently reported structure of LGP2 in complex with a short dsRNA oligonucleotide (Li et al. 
2009) reveals that LGP2 RD specifically recognizes RNA termini, preferentially the 5’ ends. 
Interestingly, when superimposing the RIG-I RD structure with the LGP2 RNA complex, the 5’ 
end recognition site within LGP2 co-localizes with the predicted triphosphate recognition site 
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of RIG-RD. Crucial residues like K858 and I875 are in direct proximity to the overlaid RNA 
structure, and well positioned to coordinate a triphosphate extension. Although the exact 
molecular details of the RIG-I RD RNA interaction can only be inferred from an 
experimentally derived co-complex structure, it seems that recognition of nucleic acids by 
RIG-I and LGP2 follows common principles. In both cases, small modifications of the RD 
scaffold allow for specific recognition of RNA-end structures. 
4.2 RIG-I Integrates Two Pathogen-Associated 
Molecular Patterns 
Functional analysis of RIG-I revealed that dsRNA as well as single stranded RNA with 5’-
triphosphate extensions can induce enzyme activation (Figure 11). These two distinct viral 
patterns are also sensed by two separate domains within RIG-I. Whereas the RD seems to 
be crucial for recognizing 5’-triphosphate end structures, the helicase domain binds and 
requires dsRNA to activate its ATPase-mediated translocation activity. In vivo, both patterns 
are most likely present on one RNA and are probably also required for a full antiviral 
response. This hypothesis seems challenged by the finding that ex vivo, single stranded 
pppRVL alone is a very potent RIG-I activator. However, it is very likely that pppRVL is not 
strictly single-stranded but also forms double-stranded RNA structures. Bioinformatic 
analysis of the rabies virus leader sequence revealed an intrinsic tendency of pppRVL to 
form double-stranded hairpins (Schmidt et al. 2009). Furthermore, there is accumulating 
experimental evidence that the active species in T7 polymerase transcripts, such as pppRVL, 
is actually a byproduct resulting from template switching of the polymerase. The resulting 
RNA would have an extended intrinsically complementary sequence, which would trigger 
hairpin formation (Schmidt et al. 2009). Therefore, the 5’-triphosphate motif of such an RNA 
would be recognized by RD whereas the double stranded parts would simultaneously and 
cooperatively activate the helicase domain. In line with this model, the molecular dimensions 
of the RIG-I RD allow for recognition of the 5’-triphosphate end plus a maximum of three 
additional nucleotides only. It is therefore highly likely that, in the context of the full-length 
protein, 3’ protruding nucleotides forming double-stranded structures will reach the helicase 
domain to induce full activation of the protein. 
4.3 CARDs Play a Dual Regulatory Role  
The RIG-I CARDs seem to have two opposing functions: they act (1) as a negative regulator 
of the helicase (ATPase) domain, potentially by sterically blocking access to the dsRNA 
binding sides in the helicase (DECH box) motif and (2) as the positive mediator of 
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downstream signaling by facilitating CARD / CARD interaction with the adaptor molecule 
IPS1. Deletion of the complete CARDs results in the loss of preference for 5’-triphosphate 
RNA so that the truncated RIG-I is now equally-well stimulated by dsRNA bearing unmodified 
ends. In comparison, the RIG-I splice variant, which harbors a deletion in the N-terminal 
CARD, loses its capability to interact with IPS1 but retains its auto-inhibition of the ATPase 
activity. The observed up-regulation of RIG-I SV expression after induction of anti-viral 
signaling therefore may represent a potent negative feedback mechanism. Signaling 
defective RIG-I splice variant would then sequester viral RNA into inactive hetero-complexes, 
thereby shutting off again the anti-viral signaling cascade, once sufficient activation has 
occurred. 
4.4 Proposed Model for RIG-I Activation 
In summary, the data presented here suggest a step-wise model of RIG-I activation, which 
can be described as the following chain of events (Figure 22). In the inactive form, RIG-I is 
monomeric and arranged in a conformation in which the CARDs are buried within the 
helicase domain, blocking the access of and subsequent stimulation by dsRNA species. This 
is demonstrated by the observed inhibitory effect of the CARDs on RIG-I ATPase activity 
when stimulated with dsRNA. Upon binding of RNA bearing a 5’-triphosphate modification, 
RD mediates dimerization of the protein (Cui et al. 2008). Furthermore, via an extensive 
conformational change of the CARDs, the helicase domain becomes exposed and is now 
free to interact with dsRNA. Activated RIG-I now presumably translocates on dsRNA in an 
ATP dependent manner (Myong et al. 2009), thereby exposing the CARDs for downstream 
interaction with IPS-1. What might be the functional relevance of the RIG-I translocation 
activity? First, by moving on dsRNA RIG-I might effectively displace viral proteins, thereby 
interfering with viral replication and de-masking viral patterns. Furthermore, if RIG-I in 
translocation mode actually represents the actively signaling form of the protein, then signal 
strength would be limited by the time spent in translocation mode. This might explain why 
RIG-I and MDA5 differ in their ability to signal in response to long double-stranded RNA. 
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Figure 22: Proposed model for RIG-I activation. 
Schematic illustration of events leading to RIG-I activation. In the inactive state, the RIG-I CARDs block access 
to the helicase domain (DECH). Binding of the 5’-triphosphate motif to the RD induces dimerization. 
Subsequently, the CARDs undergo a large conformational change, exposing themselves to interact with 
downstream signaling factors. In addition, the helicase (DECH) domain mediates ATP-dependent translocation 
on dsRNA parts. 
4.5 Hypothetical Modes of Viral Recognition by MDA5 
Since poly I:C is sufficient for stimulation in vitro, the physiological ligand recognized by 
MDA5 is most likely only composed of nucleic acids as well. However, so far no defined 
molecular (RNA) epitope could be found that is responsible for MDA5 induction. The here 
conducted functional ATPase assays demonstrated that a double stranded oligonucleotide is 
needed to induce MDA5 ATPase activity. Most likely, the length of the double strand is an 
important criterion, as has also been implicated in an independent study (Saito and Gale 
2008). Recently, there has been accumulating evidence that MDA5 might not function alone 
but rather in concert with LGP2 (Venkataraman et al. 2007; Pippig et al. 2009). If this holds 
true, LGP2 might augment MDA5 dependent signaling, which would explain the difficulties in 
stimulating MDA5 on its own. However, an LGP2 / MDA5 complex could not be reconstituted 
in vitro and addition of LGP2 had no synergistic effect on MDA5 ATPase activity (data not 
shown). In a physiological scenario, LGP2 and MDA5 might interact in a rather transient 
manner, although such interactions would be difficult to trap with biochemical methods. 
Furthermore, as yet unidentified factors might bridge a functional LGP2 / MDA5 complex and 
might explain why the individual protein components fail to interact directly in vitro. 
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4.6 V-Protein Interferes with Helicase Activity of MDA5 
and Thereby Inhibits Signaling 
Mapping the interaction of MDA5 and Paramyxovirus V-protein by peptide SPOT analysis as 
well as co-expression of truncation variants revealed a stable complex between the N-
terminal RecA domain of MDA5 and V-protein. It was shown that sequestration of viral RNA 
by V-protein is not the mechanism of MDA5 inhibition. Rather, RNA is still able to bind to a 
MDA5-V-protein complex. Therefore V-protein binding most likely freezes MDA5 in a state 
which is incapable of ATP hydrolysis. Since integrity of the ATPase is necessary for 
downstream signaling the antiviral response is thereby severely attenuated. A model for the 
inhibitory role of V-protein is depicted in Figure 23. 
 
Figure 23: Model for MDA5 inhibition by V-protein. 
Binding of V-protein to the N-terminal RecA domain (RecA N) prevents ATPase activity in the presence of viral 
RNA patterns (long dsRNA). The V-protein MDA5 complex is incompetent of antiviral signaling. 
4.7 MDA5 RD Structurally Resembles RIG-I RD 
The structural data reported here suggest that the RDs of MDA5 and RIG-I are closely 
related in fold and share a common RNA binding core. Although both domains harbor a 
similar, positively charged patch, that is ideally suited for RNA recognition, MDA5 has a 
substantially lower affinity for RNA ligands. This is most likely due to subtle differences in the 
key side chains forming the binding pocket. For instance, residue K858RIG-I, which has been 
shown to be essential for RNA recognition in RIG-I is not conserved in MDA5 (Figure 20). 
During the course of this thesis, a crystal structure of MDA5 RD was published in the protein 
data bank (Protein Data Bank Accession Code 3GA3). By comparing the experimentally 
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derived structure with the theoretically calculated model it is now possible to evaluate the 
reliability of the structure prediction performed in this work (Figure 24). 
 
Figure 24: Comparison of the theoretical MDA5 RD model with the experimentally derived 
crystal structure. 
Overall, the MDA5 RD model (dark blue ribbon) and the MDA5 RD crystal structure (light blue ribbon) 
superimpose well on each other. Slight aberrations are visible in flexible loop regions and the C-terminal α-
helix. 
Overall, the predicted MDA5 RD structure fits the experimentally determined crystal structure 
very well. Not surprisingly, the flexible loop regions and the C-terminus, which was artificially 
modified (His-tag) in the crystal structure, vary in conformation. Indeed, MDA5 harbors a 
similar positively charged patch as has been shown for RIG-I. This successful example of 
structural prediction clearly illustrates the power of current homology structural modeling. 
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5 Summary 
The cytosolic helicases RIG-I and MDA5 are primary sensors for viral RNA during infection. 
Although their overall role as key players in the antiviral response and the induced signaling 
pathways have been elucidated in great detail over the past years, a structural and functional 
understanding of virus recognition by these sensors is missing.  
On the basis of an X-ray structure of RIG-I RD the 5’-triphosphate interaction site could be 
mapped to a previously identified positively charged groove, employing structure-guided 
mutants in RNA binding assays. Structural modeling of the homologous RD of MDA5 
implicated that it possesses an overall similar fold and a positively charged binding groove. 
However, crucial residues for RNA binding in RIG-I RD are not conserved in MDA5, 
explaining its low affinity to RNA. In the context of the full length protein, RIG-I RD has an 
important regulatory role on the RIG-I ATPase domain, since its removal drastically impaired 
ATPase activity. In contrast, the CARDs seem to negatively regulate RIG-I ATPase activity. 
Based on a comparison of enzymatic activities of several RIG-I truncation variants, a model 
was postulated in which the CARDs block access of RNA to the helicase motif in the inactive 
state of RIG-I. Upon recognition of the RNA 5’-triphosphate motif by RD, RIG-I undergoes a 
conformational change which exposes the CARDs, allowing downstream signaling to IPS-1 
as well as binding of RNA to the helicase motif. A collaborative study revealed that RIG-I 
actively translocates on dsRNA. Furthermore, these experiments emphasized that RIG-I acts 
as a receptor which integrates a binary molecular pattern. Besides the 5’-triphosphate end 
structure, which is recognized by RD, double stranded RNA parts bind to the helicase domain 
and induce ATP-dependent translocation.  
In contrast to RIG-I, the molecular patterns which lead to MDA5-dependent anti-viral 
signaling are not sufficiently understood. This work has shown that the dsRNA-mimic poly I:C 
is a potent activator of MDA5 ATPase activity in vitro, in analogy to its stimulatory effect in 
cell culture experiments. Interestingly, ATPase activity is inhibited by V-protein, which stably 
binds to the N-terminal RecA domain of the MDA5 helicase domain. The V-protein mediated 
inhibitory effect seems to be caused by its interference with ATP hydrolysis directly, rather 
than RNA sequestering or preventing MDA5 RNA interactions.  
In summary, the results presented here broaden our understanding of virus sensing and 
pinpoint several intriguing avenues for future research. 
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6 Introduction 
6.1 Green Fluorescent Protein: From Initial Discovery 
to its Revolutionary Impact on Live Cell Imaging 
The jellyfish Aequorea Victoria is a bioluminescent habitant of the Pacific Ocean, emitting 
green light. In the early 1960s, Osamu Shimomura and colleagues found that the active 
component of Aequorea bioluminescence is the protein aequorin, emitting blue light in a Ca2+ 
dependent manner (Shimomura et al. 1962). The green appearance of Aequorea is due to a 
second protein, absorbing the blue light via radiationless Förster resonance energy transfer 
(FRET) and emitting it again in the green spectral range. This protein was consequently 
named green fluorescence protein (GFP) (Shimomura et al. 1962; Cormier et al. 1973). By 
proteolytic digestion of GFP, Shimomura could finally identify the actual chromophore as 
being a p-hydroxybenylidenimidazolinone moiety (Shimomura 1979). The crucial 
breakthrough for the application of GFP in cell biology came along with the cloning of the 
gene by Douglas Prasher, more than 30 years after its initial discovery (Prasher et al. 1992). 
Martin Chalfie was the first to express GFP in other organisms than jellyfish, namely E. coli 
and C. elegans (Chalfie et al. 1994). Importantly, recombinantly expressed GFP retained its 
fluorescence properties, which implicated that the fluorescence does not require any other 
component specific to Aequorea victoria. Furthermore, GFP could be fused to proteins 
without influencing their activity, which demonstrated its virtually unlimited potential as a 
universal genetic tag in biological research (Wang and Hazelrigg 1994). Roger Tsien’s 
laboratory demonstrated that chromophore formation by the side chains of Ser65-Tyr66-
Gly67 is dependent on oxygen, since anaerobically expressed GFP did not fluoresce (Heim 
et al. 1994). Importantly, the fluorescence of such non-fluorescent GFP could be restored by 
adding oxygen. Based on these results, they proposed a chemical mechanism for 
chromophore formation with molecular oxygen as the only auxiliary factor. The same group 
engineered a series of point mutation variants with profound effects on the GFP spectral 
properties (Heim and Tsien 1996). A milestone on the way to rational design of superior GFP 
variants was the solution of the GFP crystal structure (Ormo et al. 1996; Yang et al. 1996). 
The nowadays most widely used enhanced GFP (eGFP) carrying several structure-guided 
mutations, is characterized by a higher brightness, less photobleaching and a single and 
amplified excitation peak. Recently, several other fluorescent proteins have been developed, 
most of them originating from the red fluorescent protein of Discosoma, covering a broad 
range of the visible spectrum (Shaner et al. 2005). The thus obtained variety of 
chromophores laid the cornerstone for the more complex bio-imaging techniques such as 
fluorescence resonance energy transfer (FRET) or induced photoactivation (Patterson and 
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Lippincott-Schwartz 2002; Zhang et al. 2002) used today. For their enormous contributions 
“to the discovery and development of the green fluorescent protein, GFP”, Osamu 
Shimomura, Martin Chalfie and Roger Tsien got awarded with the Noble Prize in Chemistry in 
2008. 
 
Figure 25: Bioluminescence of the jellyfish Aequorea Victoria. 
(A) The jellyfish Aequorea Victoria in its natural habitat, the Pacific Ocean (Wikimedia Commons) and (B) 
scheme of the origin of its green fluorescence. 
6.2 Green Fluorescent Protein: Biophysical and 
Structural Properties 
As was already deduced from comparing the spectral properties of a fluorescent GFP 
peptide fragments to spectrometric properties of reference substances, the GFP 
chromophore contains a p-hydroxybenzylidenimidazolinone moiety (Shimomura 1979). It is 
formed out of the amino acid residues Ser65-Tyr66-Gly67 in the wild-type protein (Prasher et 
al. 1992). Figure 26 shows the suggested mechanism of chromophore formation (Heim et al. 
1994).  
 
 
 
 
 
 
 
Figure 26: Catalytic mechanism of GFP chromophore formation. 
Schematic illustration of the intramolecular chromophore biosynthesis with the estimated rate constants (Tsien 
1998). 
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After having folded into an almost native conformation, the imidazolinone is formed by 
nucleophilic attack of the amide of Gly67 on the carbonyl of residue 65, followed by 
rehydration. In a final step, molecular oxygen dehydrogenates the α-β bond of residue 66 to 
put its aromatic group into conjunction with the imidazolinone. Only at this stage does the 
chromophore acquire visible absorbance and fluorescence. GFP has a quite complex 
absorption and emission spectrum (Heim et al. 1994). The original wild type GFP is 
characterized by a dual-peak excitation spectrum with a major absorption maximum at 395 
nm and a minor one at 477 nm (Figure 27). Excitation at either wavelength results in the 
emission of green fluorescence at around 507 nm. The dual absorption of GFP is due to two 
alternative states of the chromophore, which are interconvertible by photoisomerization. The 
neutral phenol state absorbs at 395 nm whereas the deprotonated phenolate anion absorbs 
at 477 nm (Heim et al. 1995). Because of light-induced anionization, the neutral 
chromophore gives emission in a similar range as the anionic chromophore as has been 
shown by picosecond spectroscopy (Chattoraj et al. 1996). Mutations within the chromophore 
environment have a great impact on the spectral properties of GFP. The mutation Ser65T, 
which among other mutations is incorporated in the eGFP variant, leads to a suppression of 
the 395 nm excitation peak while the peak at longer wavelength is increased five- to sixfold in 
amplitude and shifted to 490 nm (Figure 27) (Heim et al. 1995). 
 
Figure 27: GFP excitation and emission spectra. 
Excitation spectra of wild-type GFP (wtGFP) and enhanced GFP (eGFP) are shown as solid- and emission 
spectra as dotted line. The respective state of the chromophore is depicted above (Tsien 1998). 
Although GFP had already been crystallized in the 1970s (Morise et al. 1974), the crystal 
structure of GFP was only reported 26 years later (Ormo et al. 1996; Yang et al. 1996). GFP 
consist of 238 amino acids, but only 229 residues are visible in the structure. Residues 1 and 
230-238 were too disordered to be resolved. The protein folds into an 11-stranded β barrel 
which is wrapped around a single central helix. The barrel forms a cyclinder with a length of 
42 Å and a diameter of 24 Å (Figure 28A). The ends of the cylinder are capped by short, 
distorted helical segments and loops. The chromophore is integrated in the central helix, 
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thereby being completely protected from bulk solvent. The p-hydroxybenzylidenimidazolinone 
is embedded into a complex network of hydrogen bonds and polar interactions with 
surrounding amino acids and water molecules (Figure 28B and C). Comparison of the 
wtGFP structure to the S65T mutation gave a structural rational for the observed changes in 
the excitation spectrum (Brejc et al. 1997). The main differences between both structures are 
found in the chromophore environment. The observed differences are due to the presence of 
an additional methyl group in the S65T mutation in comparison to the wild-type. The authors 
suggest a complicated rearrangement of the hydrogen bond network (Brejc et al. 1997). As a 
consequence, the negative charge of the phenolate state of the chromophore is stabilized in 
the S65T mutant, leading to the described spectroscopic changes. 
 
Figure 28: Structure of GFP and its integrated chromophore. 
(A) Ribbon presentation (grey) of the GFP β-barrel (Yang et al. 1996) with the chromophore shown as colored 
spheres. Structural comparison of the chromophore environment of the wtGFP (B) and comparison to the GFP 
S65T mutation (C) according to Brejc. et al. 1997. 
6.3 Nanobodies as a Versatile Tool for Specific Protein 
Targeting 
The field of recombinant antibody technology has rapidly progressed over the last decade 
mainly driven by the ability of antibodies to specifically bind therapeutically as well as 
diagnostically relevant targets. However, conventional antibodies (immunoglobulins G - IgGs) 
have a major drawback, in that their recombinant expression is complicated by them being 
composed of four polypeptide chains (two heavy and two light chains, Figure 29), and being 
subject to extensive post-translational modification in vivo. Furthermore, their application 
within cells is limited by the impaired disulfide formation in the reducing environment of the 
cytosol, difficult subcellular targeting and inefficient assembly of epitope-recognizing parts of 
the variable light and heavy chain (Biocca et al. 1991; Cattaneo and Biocca 1999). A 
milestone was the discovery that antibody fragments, which consist of the N-terminal variable 
domains of heavy and light chains only (Figure 29), are sufficient for antigen binding 
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(Sundberg and Mariuzza 2002). However such Fab fragments remain difficult to express in 
microbial systems. Therefore, the discovery that camelids (bactrain camels, dromedries and 
llamas) produce functional antibodies devoid of light chains was a clear breakthrough in the 
field (Hamers-Casterman et al. 1993). Heavy-chain antibodies (HCAbs) recognize their 
antigens via a single variable domain (referred to as VHH nanobody, Figure 29), which 
presents the smallest intact antigen binding fragment (~ 15 kDa) occurring in nature 
(Muyldermans 2001). The compactness of nanobodies has multiple advantages over 
conventional IgGs and smaller Fab fragments: (1) Only one domain has to be cloned and 
expressed, (2) specific nanobodies can easily be selected by phage display libraries and (3) 
nanobodies are highly soluble and stable and can be efficiently expressed in heterologous 
systems such as E. coli (Muyldermans et al. 1994). The combination of these properties 
make nanobodies highly interesting molecules for diagnostic as well as therapeutic 
purposes. Described diagnostic applications in cell biology include targeting and tracing of 
antigens in live cells, targeted modulation of enzymes as well as the usage as immobilized 
nanotraps to precipitate protein complexes in vivo and in vitro (Muyldermans 2001; Revets et 
al. 2005; Rothbauer et al. 2006; Rothbauer et al. 2008). Nanobodies are also discussed as 
novel agents for cancer therapy and other therapeutic applications (Cortez-Retamozo et al. 
2004; Revets et al. 2005). Very recently, the first VHH successfully completed phase I clinical 
trials (www.ablynx.com). 
 
Figure 29:  Schematic illustration of antibodies and fragments thereof. 
Conventional IgGs are composed of two heavy and two light chains. The heavy chain harbors three conserved 
domains (CH) and one variable domain (VH). The light chain is composed of one variable (VL) and one 
conserved domain (CL). Fab fragment are monovalent antigen recognition domains resulting from proteolytic 
cleavage of conventional IgGs. Heavy chain antibodies are composed of two heavy chains only. The 
monovalent antigen recognition motif is formed by the VHH domain, also referred to as nanobody.  
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6.4 Structural Properties of Nanobodies 
Determination of crystal structures of VHH nanobodies alone and in complex with antigen 
have eludicated several interesting structural features (Desmyter et al. 1996; Spinelli et al. 
1996; Desmyter et al. 2002). Similar to conventional VH domains, nanobodies contain four 
framework regions (FRs) that fold into the typical immunoglobin fold, and three 
complementary-determining regions (CDRs) that are involved in antigen binding (Figure 30). 
The FRs share a high sequence conservation with conventional antibodies and their 3D 
structures are superimposable (Muyldermans et al. 2001). However, four amino acids (Val37, 
Gly44, Leu45, Trp47) that are extremely conserved in VHs are constitutively substituted in 
the nanobodies (Figure 30). In conventional antibodies these residues form the hydrophobic 
core between the VH and the VL domain (VL site). In HCAbs, they are mutated to more 
hydropholic residues due to their exposed position. Further differences between VHs and 
nanobodies are reasoned by the fact, that in the absence of the VH-VL combinatorial 
diversity, new mechanism must account for a similar variability. For HCAbs this is achieved in 
two ways; first the VL site provides an additional surface, which can be employed for antigen 
recognition. Furthermore, in comparison to VHs of human or mice, the variability of the CDR1 
and CDR2 is increased. The CDR3 of a VHH is longer than that of VHs and also more 
accessible for solvent, thus creating a larger surface for antigen interaction. On the basis of 
these structural findings, several advantages of nanobodies can be rationally explained. The 
increased solubility, stability and efficient expression are most likely due the decrease in 
hydrophobicity at the VL site. Furthermore, nanobodies have been described to recognize 
recessed antigenic sites such as enzyme active centers, which can normally not be 
contacted by conventional antibodies (Lauwereys et al. 1998; De Genst et al. 2006). This 
feature has been attributed to their smaller size and the ability of the extended CDR3 loop to 
penetrate into such sites. Importantly, it facilitates their use as highly specific enzyme 
inhibitors. 
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Figure 30: Structure-based alignment of nanobodies. 
(A) Alignment of nanobody sequences with known crystallographic 
structure with a human VH domain (Pot VH). The CDRs are shown in 
red (CDR1) green (CDR2) and purple (CDR3). Cysteines which are 
involved in disulfide bridge formation are highlighted in yellow and 
framework regions are colored grey. Adopted from Muyldermans 2001. 
VHH specific residues in the VL site are shown in magenta. (B) Crystal 
structure of the amylase D10 nanobody (AMYL D10) (Desmyter et al. 
2002). Structural motifs are shown in similar color code as described 
for (A).  
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6.5 Objectives 
While both improving GFP-fluorescence and developing spectral derivatives thereof have led 
to a dramatic upsurge in the use of GFP in cell biology, the possibility to inducibly modulate 
the fluorescence of GFP in vitro and in vivo is still lacking. To overcome these drawbacks, the 
influence of several GFP specific nanobodies on the GFP spectral properties was tested. 
Finally, two GFP-specific nanobodies with opposing effects on GFP fluorescence were 
devised: one suppresses, the other enhances the fluorescence. 
The goal of this thesis was to provide a structural understanding of the observed modulation 
of GFP fluorescence. To this end, high resolution structures of the two GFP nanobody 
complexes should be solved by X-ray crystallography. A detailed spectroscopic analysis 
should augment the conclusion eventually derived from the structural analysis. Furthermore, 
in collaboration with the group of Prof. Dr. Heinrich Leonhardt and Dr. Ulrich Rothbauer, the 
practical benefit and potential applications of GFP fluorescence modulating nanobodies in 
living cells should be demonstrated. 
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7 Materials and Methods 
The following chapter lists experimental details of the production of GFP-nanobody 
complexes and their structural and spectroscopic characterization. General materials and 
methods are not mentioned here but can be found in Part I of this thesis.  
7.1 Materials 
7.1.1 Chemicals 
Crystallization screens, crystallization grade reagents and crystallization tools were obtained 
from Hampton Research (Aliso Viejo, USA), Qiagen, (Hilden, Germany) and Jena Bioscience 
(Jena, Germany). Chemicals for crystallization were of the highest possible grade and were 
purchased from Merck (Darmstadt, Germany) or Sigma (Deisenhofen, Germany). 
7.1.2  Bacterial Strains 
Table 11: Bacterial Strains 
E.coli strain Genotype Source 
B834 Rosetta (DE3) F– ompT hsdSB(rB– mB-) met gal 
dcm (DE3) 
Novagen, Madison USA 
 
7.1.3 Preparation of Minimal Medium for Selenomethionine Expression 
All amino acids were reagent-grade L-enantiomers purchased from Sigma (Deisenhofen, 
Germany). After dissolving the components (Table 12) in 2000 ml FPLC grade water, solution 
A was autoclaved, cooled to 37°C and supplemented with 200 ml filter-sterilized solution B 
plus 125 mg selenomethionine (Calbiochem, Schwalbach, Germany). 
 
 
 
 
 
 
 
60 Materials and Methods  
Table 12: Composition of LeMaster’s medium (Hendrickson et al. 1990) 
Autoclavable solution A (2000 ml)  
Alanine 1.0 g Serine 4.166 g 
Arginine hydrochloride 1.16 g Threonine 0.46 g 
Aspartic acid 0.8 g  Tyrosine 0.34 g 
Cystine 0.066 g Valine 0.46 g 
Glutamic acid 1.5 g Adenine 1.0 g 
Glutamine 0.666 g Guanosine 1.34 g 
Glycine 1.08 g Thymine 0.34 g 
Histidine 0.12 g Uracil 1.0 g 
Isoleucine 0.46 g Sodium acetate 3.0 g 
Leucine 0.46 g Succinic acid 3.0 g 
Lysine hydrochloride 0.84 Ammonium chloride 1.5 g 
Phenylalanine 0.266 g Sodium hydroxide 1.7 g 
Proline 0.2 g Dibasic potassium phosphate 21.0 g 
Non-autoclavable solution B (200 ml)  
Glucose 20.0 g Conc. sulfuric acid 16.0 μl 
Magnesium sulphate 0.5 g Thiamine 10.0 mg 
Iron sulphate 8.4 g  
 
7.2 Methods 
7.2.1 Bioinformatic Methods 
7.2.1.1 Structure Visualization and Analysis 
Calculation of buried surface areas was performed with the protein interfaces, surfaces and 
assemblies service PISA at the European Bioinformatics Institute (http://www.ebi.ac.uk/msd-
srv/prot_int/pistart.html) (Krissinel and Henrick 2007). Superpositions of structures and 
calculation of root mean square deviation RMSD values were conducted using the CaspR 
RMSDcalc web-server (Claude et al. 2004). Images of crystal structures were prepared with 
PyMol (http://www.pymol.org). 
7.2.2 Protein Biochemistry Methods 
7.2.2.1 Protein Expression 
Nanobodies were expressed in Rosetta cells transformed with expression vector pHEN6 
containing the coding sequence of the GFP nanobody as described previously (Rothbauer et 
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al. 2008). Native GFP and eGFP cloned into the pRset5D expression plasmid were 
expressed accordingly (Rothbauer et al. 2008). Selenomethionine-containing GFP was 
expressed in E. coli strain B834 (Rosetta (DE3)) using LeMaster’s medium supplemented 
with selenomethionine (Table 12).  
7.2.2.2 Protein Purification 
All buffers and their components used for protein purification are listed in Table 7.  
For purification of C-terminally His6-tagged Enhancer or Minimizer, bacterial cell material was 
resuspended in 10 ml of lysis buffer and then sonified. After centrifugation soluble extracts 
were loaded on a pre-equilibrated 1 ml HiTrap-column (GE Healthcare; Freiburg, Germany). 
The nanobodies were eluted by a linear gradient ranging from 20 mM (Ni-NTA washing 
buffer) to 500 mM imidazol (Ni-NTA elution buffer). Elution fractions containing the Enhancer 
and Minimizer, respectively, were pooled and further purified by gel filtration on a Superdex 
75 column (GE Healthcare; Freiburg, Germany) in gelfiltration buffer. For complex purification 
of wtGFP-Enhancer and wtGFP-Minimizer complexes, purified nanobodies were pre-bound 
via their C-terminal His6-tag to a 1ml HiTrap-column (GE-Healthcare Life Sciences). 
Subsequently, wtGFP was isolated from crude cell extracts by binding to the pre-charged 
column. Complexes were eluted by increasing concentration of imidazol and separated from 
unbound protein by gel filtration chromatography using a Superdex 200 column (GE 
Healthcare; Freiburg, Germany) in gelfiltration buffer. 
Table 13: Protein purification buffers 
Buffer Composition 
Lysis buffer 500 mM NaCl, 12 mM Phosphate, 2.7 mM KCl, pH 7.4, 20 mM Imidazol, 1 mM PMSF 
Ni-NTA washing buffer 500 mM NaCl, 12 mM Phosphate, 2.7 mM KCl, pH 7.4, 20 mM Imidazol  
Ni-NTA elution buffer 500 mM NaCl, 12 mM Phosphate, 2.7 mM KCl, pH 7.4, 500 mM Imidazol  
Gefiltration buffer 20 mM Tris 7.5, 100 mM NaCl  
 
7.2.3 Fluorescence Spectrocopy 
Fluorescence assays were performed either by scanning a 96 well microplate (Nunc) on a 
Typhoon Trio (GE Healthcare, Freiburg, Germany; excitation: 488 nm, emission filter settings: 
520 nm BP 40) or using a monochromator-based microplate reader (Infinite M1000, Tecan, 
Mainz, Germany; excitation wtGFP at 395 nm or 475 nm, excitation eGFP: 488 nm and 
emission 507 nm +/- 10 nm). Increasing amounts of the respective GFP binding nanobody 
were titrated to 100 µl of 50 nM GFP in gelfiltration buffer.  
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GFP fluorescence excitation spectra were recorded with a FluoroMax-P fluorimeter (HORIBA 
Jobin Yvon). Typically, 0.5 µM protein in gel filtration buffer was measured in a 1 ml quartz 
cuvette. The band pass was 5 nm for excitation and 5 nm for emission. Samples were 
excited at 395 nm and 475 nm, respectively, and excitation spectra were recorded in the 
range of 480 nm to 600 nm.  
Fluorescence absorption spectra were recorded on a UV / Vis Spectrophotometer (Beckman 
Coulter). Absorption of 0.5 µM GFP alone and 0.5 µM GFP-Enhancer / -Minimizer 
complexes, respectively, was detected during continuous excitation steps (1 nm) from 250 
nm – 700 nm. 
All fluorescent data were analyzed using Microsoft Excel. 
7.2.4 Structure Determination by X-Ray Crystallography 
The following chapter should give a short introduction into X-ray crystallography with a focus 
on techniques employed during this thesis. A detailed description of the underlying theory 
would go far beyond the scope of this text and can be found elsewhere (Rhodes 2000; 
Drenth 2002; Giacovazzo 2003). 
7.2.4.1 Theoretical Background of X-ray Diffraction 
X-rays are electromagnetic waves, having a wavelength in the range of atomic distances   
(10-10 m = 1 Å), that interact with electrons in the outer sheets of atoms. The excited atom 
emits X-rays of the same wavelength in every direction by means of elastic scattering. 
Normally, the emitted waves scattered from different atoms interfere and cancel each other 
out. However, constructive interference can occur if the light path of the two waves differs by 
n⋅λ (n=integer) and a reflection can be recorded. Crystals are highly ordered three 
dimensional arrangements composed of unit cells related by translational symmetry. 
Therefore, X-rays diffracted from crystals can be described as a reflection from imaginary 
lattice planes. Intersections of the lattice planes with the unit cell axes are termed Miller 
Indices (h, k, l) and describe the orientation and the spacing between a set of parallel lattice 
planes. The conditions for constructive interference are given by Bragg’s Law: 
 
Only if the distance d between the parallel lattice planes and the angle θ between the lattice 
planes (h, k, l) follow Bragg’s law, a corresponding reflection (defined by the indices h, k , l) 
can be observed. With the knowledge of the positions of the reflections, the geometry of the 
unit cell can be determined. 
θλ sin2 ⋅⋅=⋅ dn
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7.2.4.2 The Phase Problem in Crystallography 
To reconstitute a three-dimensional electron density distribution of a crystallized molecule 
from the information contained in the reciprocal diffraction pattern, several parameters of 
each reflected wave have to be determined. Mathematically, the three dimensional electron 
density distribution of a molecule ( ),,( zyxρ ) can be described by the following equation: 
[ ]),,((2exp),,(1),,( lkhlzkyhxilkhF
V
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This formula represents the summation over all structure factors F (h, k, l) for each position 
(x, y, z) in a normalized unit cell (1/V). Several parameters for each diffracted wave are 
needed to calculate back to the three-dimensional model in real space via Fourier 
Transformation. The wavelength of the scattered rays is given by the wavelength of the 
incident beam. Whereas the amplitude and the position of the reflection in reciprocal space 
( ),,( lkhF ) can be directly determined from the X-ray diffraction pattern, the phase of the 
scattered reflections (α (h, k, l)) is lost during the measurement. This lack of information is 
called the “phase problem” in crystallography. Several methods have been developed to 
approximate the missing phase information. An important tool to obtain phase angles in de 
novo structure determination is the Patterson function. It comprises a Fourier Transformation 
of the measured intensities and does not depend on phases. 
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The Patterson unit cell is characterized by u, v, w coordinates and has an identical dimension 
as the real unit cell. However, the Patterson map is comprised of interatomic distance vectors 
and is usually too complicated to be directly interpreted for the location of individual atoms. 
Still, as the peak heights at the endpoints of the vectors depend on the electron number of 
the respective atom, relative positions of heavy atoms in a unit cell can be determined. 
7.2.4.3 Single and Multiple Wavelength Anomalous Dispersion 
(SAD/MAD) 
Near the absorption edge of an atom resonance effects can be observed, if the energy of the 
incident beam is close to the Eigenfrequency. In the resonance range some photons are 
emitted with the same energy but with a phase shift. This phenomenon is described as 
anomalous dispersion. Single or multiple wavelength anomalous dispersion (SAD or MAD) 
depends on the presence of one or more heavy atoms in the polypeptide chain that cause 
significant anomalous scattering. Atoms in proteins which are suitable for this purpose are 
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sulfur or heavier atoms, for example metal ions in metalloproteins. The most commonly used 
atom for phase determination via MAD, however, is selenium, since it is usually possible to 
replace the natural sulfur containing amino acid methionine by selenomethionine. With the 
increased availability of synchrotron sources, which provide tunable X-ray beams over a 
broad spectrum of wavelengths, this technique has nowadays developed into the most 
widely used method for experimental phasing of protein structures. 
While in normal scattering, the structure factors have the same amplitude and opposite 
phases according to Friedel’s Law, anomalous scattering causes violation of Friedel’s Law.  
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where
ano
FΔ is the difference between the structure factors of the related Bijvoet pair 
),,( lkhFPH  and ),,( lkhFPH −−−  scaled up by the factor f’/2f’’. With help of a Patterson map 
calculated with 
ano
FΔ 2 the amplitude of structure factor ( HF ) and the phases (αH) of the 
heavy atoms can be determined. Ultimately, the protein phase angle can be estimated (αP) 
by the following equation, 
HHPPPH FFF αα +=  
where FPH is the structure factors of the derivate crystal and PF  is the amplitude of the 
protein structure factor. 
As anomalous scattering depends on the wavelength, usually three wavelengths (peak, 
inflection and remote) are recorded in a MAD experiment. In comparison to a SAD 
experiment, where anomalous data is recorded at a single wavelength only, MAD allows 
more precise phase estimation. 
7.2.4.4 Molecular Replacement 
Another way of solving the phase problem in X-ray crystallography is the molecular 
replacement method (MR). This however requires the existence of a structurally related 
search model. The search model can consist of already solved parts of the unknown 
structure; alternatively a close structural homolog can be used. Because of the increasing 
number of known structures deposited in the protein data bank (PDB), the latter approach 
becomes more and more feasible. In order to obtain useful phase angles of the unknown 
structure, the search model has to be oriented in the electron density of the unknown 
structure. The replacement is a six-dimensional search problem, which can be broken down 
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into a three-dimensional translation and a three-dimensional rotation search. In a primary 
rotation search the intramolecular vectors, which were derived from the Patterson function 
and depend on the orientation of the molecule only, are correlated with the search model. 
The consecutive translational search uses intermolecular cross vectors, which depend on 
both the orientation and the position of the molecule. The derived coordinates of the search 
model in the unit cell then allow the calculation of a new structure factor amplitude calcF  and 
an estimation of the respective phase angles αcalc. The calculated phase angles αcalc can then 
be combined to measured structure amplitudes obsF  resulting in an estimate of the structure 
factor.  
=)(hF ))(exp()( hihF calcobs α⋅  
The use of )(hcalcα in calculating the electron density map results in a bias towards the model 
structure employed to generate the phase angles. Therefore, an electron density map is 
typically obtained from structure factors which are weighted towards obsF  to minimize model 
bias, according to the following equation.  
()( =hF 2 ))(exp())()( hihFhF calccalcobs α⋅−  
7.2.4.5 Crystallization and Structure Determination of the GFP-
Enhancer and the GFP-Minimizer Complex  
Purified GFP-nanobody-complexes were crystallized by hanging drop vapor diffusion. 1 μl of 
protein solution at 10 mg/ml concentration was mixed with 1 μl of the reservoir solution 
(native GFP-Enhancer. 0.1 Citrate pH 4.0, 1.6 M Am2SO4), (Selenomethionine (SeMet)-GFP-
Enhancer: 60% (v/v) MPD, 100 mM NaAc pH 4.6, 10 mM CaCl2), (GFP-Minimizer: 100 mM 
Mes pH 6.5, 30% (v/v) PEG8000, 15% (v/v) Glycerol).  
Crystals of native and SeMet-GFP-Enhancer grew after one week at 20°C and were flash 
frozen in liquid nitrogen. Native GFP-Enhancer crystals were recorded at the X06SA 
beamline (Swiss Light Source) to 2.9 Å. Multiple wavelength diffraction data at the K 
absorption edge of selenium were measured at the same beamline to 2.15 Å. (Table 14). 
GFP-Minimizer crystals occurred overnight and were flash frozen in liquid nitrogen the next 
day. Data collection was performed at the beamline ID29 at the European Synchrotron 
Radiation Facility to a resolution of 1.6 Å (Table 15).  
Diffraction data of the complexes were processed with XDS (Kabsch 1993). The SeMet-GFP-
Enhancer and GFP-Minimizer crystals belong to space groups P4222 and P212121, 
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respectively, with one (GFP-Minimizer) or two (SeMet-GFP-Enhancer) complexes in the 
asymmetric unit. In the case of the GFP-Enhancer structure, 3 selenium sites per complex 
were located with autoSHARP (Global Phasing, Cambridge). Single wavelength anomalous 
dispersion phasing and solvent flipping yielded an interpretable experimental electron density 
map. The models for GFP and Enhancer were built with COOT (Emsley and Cowtan 2004) 
and refined with PHENIX (Adams et al. 2002), using overall isotropic B-factors and bulk 
solvent corrections, individual B-factor refinement, simulated annealing, crystallographic- and 
positional refinement. The GFP-Minimizer structure was determined by molecular 
replacement with Phaser using an individual GFP and a nanobody polypeptide chain from 
the previously determined GFP-Enhancer structure as independent search models. The 
replacement model was manually altered with COOT and refined using similar procedures as 
described for the GFP-Enhancer structure.  
Coordinates and structure factors of the GFP-Enhancer and GFP-Minimizer complex were 
deposited to the Protein Data Bank (PDB) with accession number 3K1K and 3G9A, 
respectively. 
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8 Results 
8.1 GFP-Binding Nanobodies Modulate GFP 
Fluorescence 
The group of Prof. Dr. Leonhardt and Dr. Rothbauer and has great expertise in the 
generation of VHH nanobodies and their application in cell biology (Rothbauer et al. 2006; 
Rothbauer et al. 2008; Zolghadr et al. 2008). In foregoing work, seven VHH nanobodies from 
alpacas with strong binding to GFP were selected by phage display. The resulting GFP 
binding proteins (GBPs 1 – 7) were cloned with a C-terminal histidine (His6)-tag, expressed in 
Escherichia coli and purified by immobilized metal affinity chromatography (IMAC).  
Because it was anticipated that nanobody binding might alter GFP fluorescence properties, a 
fluorescent in vitro binding assay was performed by titrating increasing amounts of GBP1 - 7 
to wild type GFP (wtGFP). Fluorescence intensities were recorded in a 96 well microplate 
format and subsequently quantified (Figure 31A and B). Strikingly, two nanobodies, GBP1 
and GBP4, indeed had a pronounced effect on the fluorescence emission of wtGFP. 
Whereas binding of GBP1 leads to a 4-fold enhancement, binding of GBP4 drastically 
reduces the fluorescence by a factor of 5. Overall, there is a remarkable 20 fold difference in 
fluorescence between the two nanobody complexes under the conditions applied. Attributing 
to their observed impact on GFP fluorescence GBP1 and GBP4 were termed Enhancer and 
Minimizer, respectively.  
 
Figure 31: Identification of fluorescence modulating nanobodies. 
(A) Titration of seven unique GFP binding nanobodies (GBP1 – 7, 0 – 50 nM) on purified GFP (50 nM / well). 
After complex formation, the signal intensity of GFP was detected by laser scanning (excitation 488 nm) (B) 
Quantification of the measurements shown in (A) with +/- standard deviation (S.D.) depicted as black bars. 
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The augmented fluorescence of the Enhancer–GFP complex is comparable to the improved 
spectral properties of eGFP. This let to the question, whether the Enhancer might be able to 
even further increase the optimized fluorescence of eGFP. Indeed, binding of Enhancer to 
eGFP resulted in an additional fluorescence increase of about 1.5–fold. In contrast, binding 
of Minimizer dramatically reduced the fluorescence of eGFP by a factor of 8 (Figure 32).  
 
Figure 32: Effect of Enhancer and 
Minimizer on eGFP fluorescence. 
(A) Titration of Enhancer and Minimizer, respectively (0 
– 50 nM) on purified eGFP (50 nM / well). After 
complex formation, the signal intensity of GFP was 
detected by laser scanning (excitation 488 nm) (B) 
Quantification of the measurements shown in (A) with 
+/- S.D. depicted as black bars. 
 
 
 
 
 
Based on the opposing effects of Enhancer- and the Minimizer-binding it was tested how 
GFP fluorescence is modulated in the presence of both nanobodies (Figure 33A). 
Interestingly, after a primary addition of Enhancer, GFP fluorescence increases, and is only 
slightly reduced by the consecutive addition of Minimizer. However, when Minimizer is added 
first, the reduction of fluorescence can be completely reversed by subsequent addition of 
Enhancer (Figure 33B).  
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Figure 33: Modulating GFP fluorescence with nanobodies. 
(A) Upper row: wtGFP (50 nM) was either mock incubated, incubated with equimolar amounts of Enhancer or 
Enhancer was added followed by the addition of equimolar amounts of Minimizer. Lower row: same 
experimental set up as above but with Minimizer being added first. (B) Quantification of fluorescence data. 
Represented here are means of 3 independent experiments +/- S.D. The order of the sequential incubation 
with Enhancer and Minimizer is indicated below. 
Thus, binding of both nanobodies seems to be mutually exclusive. Although the ability of 
Enhancer to replace Minimizer at equimolar concentrations indicates a higher affinity, no 
significant difference in binding constants (Kds) could be detected. Both nanobodies have a 
Kd <1 µM as was determined by Attana continuous flow measurements (data not shown). 
8.2 Purification and Crystallization of the GFP-Enhancer 
and GFP-Minimizer Complexes 
Prerequisite for protein crystallography is a highly pure protein sample. The GFP-Enhancer 
and GFP-Minimizer complex were constituted by first coupling the GFP binding nanobodies 
to Ni-NTA material via their C-terminal His6-tags and then using the pre-charged material to 
capture GFP in a second affinity step. To separate the GFP-nanobody complexes from an 
excess of unbound nanobodies, a final gelfiltration purification step was performed. Whereas 
the GFP-Enhancer preparation contained an excess of unbound nanobodies which eluted at 
a higher retention volume the GFP-Minimizer preparation eluted in a single peak 
corresponding to a 1:1 complex (Figure 34). In both cases, the complex fractions (Figure 34; 
peak 1) were pooled and concentrated to ~10 mg/ml. 
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Figure 34: Purification of GFP nanobody complexes. 
Gelfiltration profiles and SDS-PAGE analysis using Coomassie staining of (A) the GFP-Enhancer and (B) the 
GFP-Minimizer complex, respectively. (A) Excess of Enhancer after Ni-NTA affinity purification could be 
separated from GFP-Enhancer complex (peak 2 and 1, respectively). Molecular weight standards (MWS) for 
SDS-PAGE are indicated. (B) GFP-Minimizer complex preparation is stoichiometric (1:1) after Ni-NTA affinity 
purification and results in a single peak. 
The concentrated protein samples were used for initial crystallization screening. Small 
needles of the GFP-Enhancer were found in one particular crystallization condition (Figure 
35A) after several days of incubation. By evaluating the effects of a series of additives, the 
original condition could be significantly improved. The crystals now grew to substantially 
bigger size (100 x 200 x 10µm) (Figure 35B). Nevertheless, these crystals were quite flat in 
shape and stayed mostly attached to the surface of the well which hindered crystal transfer. 
The best crystals were obtained when using complexed GFP without C-terminal His6-tag. 
Because of the nanobody mediated capturing step during complex purification, the His6-tag 
on GFP became dispensable. The improved GFP-Enhancer complex reproducibly 
crystallized in freely floating hexagons of ~ 100 x 100 x 70 µm in dimension (Figure 35C). 
Before flash freezing the crystals in liquid nitrogen, the crystallization buffer was 
supplemented with 20% (v/v) glycerol. As became obvious during subsequent structure 
determination, the resulting diffraction data was insufficient for a complete structural 
refinement (chapter 8.4). Therefore Enhancer-complex containing selenomethione labeled 
GFP was employed in further crystallization trials. Surprisingly, substitution of methionine to 
selenomethionine within GFP dramatically changed the conditions in which GFP-Enhancer 
crystals could be obtained. Whereas previous crystals grew in high concentrations of 
ammonium sulfate, the selenomethione containing complex crystallized in 60 % (v/v) 2,4-
methylpentadiol (Figure 35D). Notably, these crystals were also different in shape, growing 
as cubes of a size of ~ 50 x 50 x 50 µm. The crystals were directly flash frozen and stored in 
liquid nitrogen until measurement.  
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Figure 35: Crystal refinement of the GFP-Enhancer complex. 
(A) Initial small needles obtained in commercial screens (0.1 M NaAc 5.0, 2M Am2SO4). (B) Improved crystals 
after additive screen of the initial condition (0.1 M NaAc 5.5, 1.7 M Am2SO4, 0.1 M Am2HCitrate). Crystals grew 
as two-dimensional thin plates. (C) Further improved hexagonally shaped crystals resulting from new GFP 
construct design (buffer condition: 0.1 Citrate 4.0, 1.6 M Am2SO4). (D) GFP-Enhancer crystals of 
selenomethionine labeled GFP grew in a new, chemically deviant condition (60% (v/v) MPD, 100 mM NaAc 
4.6, 10 mM CaCl2). 
In contrast to the quite complicated crystallization of the GFP-Enhancer complex, crystals of 
the GFP-Minimizer occurred overnight in several conditions of the initial screen. Figure 36 
shows an image of crystals which were subsequently employed for data collection. The 
crystals grew in branched bars of 50 x 20 x 20 µm in dimension. Strikingly, the fluorescence 
modulation effect of nanobody binding to GFP fluorescence which was first observed in 
solution was also visible in the crystal state. Interestingly and reflecting their fluorescence 
properties, GFP-Enhancer crystals appeared in a bright green, while GFP-Minimizer crystals 
were almost colorless (Figure 35, Figure 36)  
Figure 36: Crystals of the GFP-Minimizer complex. 
Crystals obtained in commercial screens grew already 
in cryo conditions (100 mM Mes 6.5, 30% (v/v) 
PEG8000, 15% (v/v) Glycerol) and were subjected to 
data collection after flash freezing. 
 
 
8.3 Data Collection 
Native as well as selenomethionine-containing crystals of the GFP-Enhancer complex were 
measured at the X06SA beamline (Swiss Light Source) using a PILATUS 6M detector. Native 
data sets were recorded over an oscillation range of 90° (oscillation rate 1°) to a resolution of 
2.9 Å and at a wavelength of 1.00 Å. Selenomethionine-containing crystals were measured at 
the selenium K edge. The optimal wavelengths were determined with a fluorescence scan 
prior to data collection (Figure 37A). Finally, data at the peak wavelength (12.66007 keV, f’ = 
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-8.350 and f’’ = 6.102), the inflection point (12.65760 keV, f’ = -10.857 and f’’ = 3.648) and the 
high remote (12.758206 keV) were collected.  
Native data of GFP-Minimizer crystals were collected at the beamline ID29 at the European 
Synchrotron Radiation Facility over an oscillation range of 90° (oscillation rate 1°) to a 
resolution of 1.6 Å and at a wavelength of 0.98137 Å using an ADSC QUANTUM Q315R 
area detector. 
 
Figure 37: Data collection of GFP-Enhancer and GFP-Minimizer crystals. 
(A) Fluorescence scan of GFP-Enhancer crystals at the K (1s) absorption edge of selene. (B) Diffraction image 
of GFP-Enhancer crystals  and (C) GFP-Minimizer crystals. 
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8.4 Structure Determination and Refinement of the 
GFP-Enhancer and GFP-Minimizer Complexes 
Table 14: Crystallographic Table for the GFP-Enhancer-Complex 
 Selenomethionine Native 
Data collection  peak   
Space group  P4222  P6122 
Cell dimensions      
    a, b, c (Å)  a= 160.5 
b= 160.5 
c= 78.8 
 a= 87.4 
b= 87.4 
c=393.8   
α, β, γ (°)  90, 90, 90  90, 90, 120 
Wavelength  0.9793  1.00 
Resolution (Å)  2.15  2.9 
Rsym   3.9 (21.8)  4.7 (31.9) 
I / σI  14.35 (2.25)  20.93 (4.49) 
Completeness (%)  99.3 (989)  99.3 (97.2) 
Redundancy  3.13  3.85 
     
Refinement   
Resolution range (Å) 46.00-2.15 30.00-2.9 
No. reflections 56271 31056 
Rwork / Rfree 21.3. / 25.5 31.2 / 35.0 
No. atoms   
    Protein 5385 not specified 
    Water 407 not specified 
B-factors   
    Protein (Å2) 46.5 76.95 
    Solvent (Å2) 48.4 not specified 
R.m.s deviations   
    Bond lengths (Å) 0.008 0.009 
    Bond angles (°) 1.14 1.677 
 
The native GFP-Enhancer dataset was indexed and scaled with a hexagonal bravais lattice. 
The rotation function indicated a six-fold symmetry. By analyzing the systemic absences an 
additional screw axis was identified. However, discrimination between the two 
enantiomorphic space groups P6522 and P6122 was impossible at this stage. Therefore the 
molecular replacement was performed with both space groups using the GFP structure (PDB 
ID 1GFL) and a llama VHH structure (PDB ID 1I3V) as two independent search assemblies 
(Yang et al. 1996; Spinelli et al. 2001). Only the replacement with space group P6122 
resulted in a unique solution. Here, two GFP-Enhancer complexes were found in the 
asymmetric unit. Despite intensive efforts, employing non-crystallographic symmetry, all 
available refinement methods and manual model building, the refinement got trapped at an 
insufficient R factor (Rwork 31.2, Rfree 35.0). In consequence of the observed difficulties during 
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refinement, the obtained structure probably has a very strong model bias, which had not 
been overcome. Alternatively, the data sets may have suffered from crystal twinning. The 
statistics of the preliminary refinement can be found in Table 14. 
The peak data set collected from a single selenomethionine containing GFP-Enhancer 
crystal was indexed and scaled with space group P4222. Three of four selenium sites in GFP 
could be located and a continuous electron density was generated after single anomalous 
wavelength dispersion (SAD) phasing and solvent flattening (Figure 38). Automatic model 
building was followed by manual modifications and iterative refinement steps which resulted 
in a final model with good stereochemistry and an R factor of 21.3. (Rfree 25.5). Refinement 
statistics are listed in Table 14.The high-resolution data set of GFP-Minimizer crystals was 
integrated assuming P212121 symmetry. Molecular replacement using the previously 
determined structure of GFP and Enhancer as independent search models resulted in a 
unique solution. The model was manually altered and gradually refined, resulting in a final 
model with an R factor of 16.1 (Rfree 19.4). Table 15 summarizes the refinement statistics.  
8.5 Structure of GFP-Enhancer and GFP-Minimizer 
Complexes 
To reveal the molecular mechanism underlying the observed fluorescence modulation crystal 
structures of the GFP-Enhancer and GFP-Minimizer complex were determined to 2.15 and 
1.6 Å resolution, respectively. Strikingly, both nanobodies recognize two different, slightly 
overlapping epitopes on the GFP surface (Figure 39A and B). Thus, the observed 
competition for binding seems to result from a sterical clash between the nanobodies. 
Enhancer binds wtGFP in a front-wise manner at an exposed loop region between GFP β-
strand 6 and 7 as well as parts of β-strand 8, making specific contacts with all three 
complementarity determining regions (CDRs) of the nanobody (Figure 39A). Previous 
structural studies of nanobodies have shown that the CDR3 normally folds over the 
framework-2 region that in the case of classical antibodies binds to the variable domain of 
the light-chain (VL). In contrast, the extremely short CDR3 of Enhancer is stretched out, 
thereby making the framework-2 region solvent-accessible in the antigen-free form. 
Surprisingly, this entire framework-2 area participates in GFP-recognition, contrasting the 
structure of classical antibodies where it would contact the VL-domain. Interestingly, the 
majority of the specific contacts are formed between CDR3 and GFP, whereas CDR1 and 2 
remain solvent exposed. Notably, the interaction between GFP and Enhancer is 
predominantly electrostatic, spanning an interface of 672 Å2 (Table 16). An additional non-
polar contact is mediated by Phe98Enhancer, which binds a hydrophobic surface patch on GFP, 
formed by Ala206GFP, Leu221GFP and Phe223GFP. 
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Table 15: Crystallographic Table for the GFP-Minimizer Complex 
Data collection  
Space group P212121 
Cell dimensions    
    a, b, c (Å) a= 50.78, b= 81.62, c= 94.48  
Wavelength 0.98137 
Resolution (Å) 1.5 
Rsym  5.7 (39.1)* 
I / σI 16.91 (2.84) 
Completeness (%) 97.5 (86.3) 
Redundancy 3.85 
  
Refinement  
Resolution range 
(Å) 
47.00-1.61 
No. reflections 49989 
Rwork / Rfree 16.1 / 19.4 
No. atoms  
    Protein 2818 
    Water 685 
B-factors  
    Protein (Å2) 13.7 
    Solvent (Å2) 30.1 
R.m.s deviations  
    Bond lengths (Å) 0.005 
    Bond angles (°) 1.04 
 
 
Figure 38: Experimentally determined electron density of the GFP-Enhancer complex. 
Multiple wavelength anomalous dispersion map of the GFP Enhancer complex at 2.5 Å resolution after solvent 
flattening. Selene sides are shown as magenta spheres. The characteristic β-barrel fold of GFP can be easily 
identified. 
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Figure 39: Structural overview of GFP nanobody complexes. 
Overall structure of the (A) GFP-Enhancer and (B) the GFP-Minimizer complex (ribbon presentation). The GFP 
molecules are colored in green and the nanobodies in raspberry (Enhancer) and orange (Minimizer), 
respectively. (C) Sequence alignment of nanobodies with GFP contacting residues colored in green. 
Framework regions and complementary determining regions (CDRs) are annotated. Residue numbering is 
according to Kabat (Kabat and Wu 1991). 
The Minimizer binds GFP in a sidewise orientation, employing its elongated CDR3 to target 
β-strand 6 and 7 of GFP (Figure 39B). The interaction with GFP is quite remarkable, since 
the nanobody targets the rigid and flat side rather than the more flexible and easily 
accessible loops at the top and the bottom of the β-can. The Minimizer occludes a slightly 
smaller surface area (652 Å2) on GFP and the overall number of contacts is less, in line with 
its ready replacement by the Enhancer in the competition assay (Figure 39C, Table 16). 
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Table 16: Salt bridges and hydrogen bonds between GFP and Enhancer  
Salt bridges and hydrogen bonds 
GFP Residue  GFP Atom  Enhancer Residue  Enhancer Atom  Distance [Å]  
Glu142  OE2  Ser33  OG  2.42 
Glu142  OE1  Ser33  OG  2.96 
Glu142  OE2  Arg35 NH2  2.54  
Tyr145  O  Asn95  ND2  2.93 
Asn 146 OD1 Asn95 ND2 3.07 
Ser147  N  Glu101 OE2  2.79 
Lys166  NZ  Glu44  OE1  2.61 
Arg168  NH1  Glu101  OE2  3.19 
Arg168  NH2  Glu101  OE1  2.82 
Arg168  NH2  Tyr37  OH  3.25  
Asp173  O  Ser58  OG  2.88 
Gly174  O  Arg35  NH1  3.08 
Ser175  O  Arg35  NH1  2.42  
Hydrophobic interactions 
GFP Residue  Enhancer Residue  
Ala206 Phe98 
Leu221 Phe98 
Phe223 Phe98 
 
8.6 Binding of Nanobodies Induces Structural 
Rearrangements in the Chromophore Environment 
In general, binding of the nanobodies has no substantial global influence on the overall fold 
of GFP. wtGFP (PDB ID 1EMB) has RMSDs of 0.310 Å (Cα atoms) and 0.357 Å (Cα atoms) 
to Enhancer and to Minimizer, respectively. From previous structural studies on GFP, 
however, it is known that already minimal perturbations in the chromophore environment can 
have vast effects on its fluorescence properties (Brejc et al. 1997). Indeed, a detailed 
comparison of the GFP-nanobody structures with previously published GFP structures 
reveals, that the GFP-Enhancer complex harbors the deprotonated, negatively charged state 
of the GFP-chromophore which has been described for GFP(S65T) (Brejc et al. 1997) 
(Figure 40A). Binding of Enhancer induces slight structural shifts in the loop region from 
amino acid Glu142GFP to His148GFP and fixes Arg168GFP in close proximity to His148GFP. The 
conformation of the Arg168GFP side chain is stabilized by direct contacts with Enhancer 
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residues Tyr37Enhancer and Glu101Enhancer. These structural rearrangements bring the proton 
donor His148GFP in very close proximity to the hydroxyl group of the GFP chromophore 
(distance 2.7 Å compared to 2.8 Å for GFP(S65T) and 3.4 Å for wtGFP). Thus, binding of the 
Enhancer likely facilitates improved proton extraction from the fluorophore hydroxyl by 
His148GFP, thereby stabilizing the phenolate anion of the fluorophore and enhancing the 
fluorescence intensity. 
Table 17: Salt bridges and hydrogen bonds between GFP and Minimizer 
GFP Residue  GFP Atom  Minimizer Residue  Minimizer Atom  Distance [Å]  
Asn 149 ND2 Val 100f O 3.12 
Tyr 151 OH Val 100f O 2.63 
Tyr 151 OH Asp100l O 3.19 
Asn 164 ND2 Tyr 100m OH 3.09 
Lys 166 N2 Asp 95  OD1 2.70 
Arg 168 NH2 Leu 100k O 2.97 
Asp 180 OD1 Thr 98 N 2.98 
Asp 180 OD2 Thr 98 OG1 2.66 
Asn 198 ND2 Val 100c O 3.05 
Tyr 200 OH Glu 44 OE1 2.64 
Asn 149 ND2 Val 100f O 3.12 
Tyr 151 OH Val 100f O 2.63 
 
In contrast, the chromophore environment of the GFP-Minimizer complex is remarkably 
different and shows similarities to the situation present in the less-fluorescent wtGFP (Brejc 
et al. 1997). Of note here, Arg168GFP is rather flexible in comparison to the Enhancer 
complex (Figure 40B). Two alternative conformations of its guanidine group could be traced 
in the electron density. In one of the conformations Arg168GFP is tilted away from His148GFP 
and instead makes specific contacts to the backbone carbonyl of Leu100iMinimizer. This 
nanobody-induced conformational modulation reduces the electrostatic forces exerted on 
His148GFP, which is in fact pulled back from the hydroxyl group of the chromophore and 
positioned with 3.5 Å distance (wtGFP: 3.4 Å), too far to efficiently stabilize the phenolate 
anion. Instead, binding of Minimizer likely stabilizes an arrangement of the chromophore-
surrounding environment, which favors the neutral phenol state of the chromophore. In 
support of this model, the fluorescence enhancement of eGFP - where the phenolate anion 
state is stabilized by an engineered mutation - by the Enhancer is only 1.5 fold compared to 5 
fold for wtGFP, while the fluorescence suppression is 8 fold, compared to 4 fold for wtGFP. 
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Figure 40: Nanobody binding to GFP and induced structural rearrangements in the 
chromophore environment. 
An enlargement of parts of the binding sites with crucial residues and the GFP chromophore (Cro66) 
highlighted as sticks. The panels on the right show the GFP chromophore environment for the GFP-Enhancer 
(A) and the GFP-Minimizer complex (B), respectively, plus a 2.15 Å and a 1.6 Å electron density map 
calculated with 2 fo–fc coefficients and contours at 1.0 s. Binding of Enhancer (A) induces slight structural 
rearrangements which bring the proton donor His148 in closer proximity to the hydroxyl group of chromophore. 
R168GFP is stabilized by direct contacts to Y37Enhancer and E101Enhancer. In the case of Minimizer binding (B), the 
guanine group of R168GFP is rather flexible. Two alternative conformations for its side chain (marked 
with * and **) were traced. One conformation is tilted away from H148GFP making specific contacts to 
L100iMinimizer. 
In summary, the two nanobodies appear to stabilize and by thermodynamic reasoning 
preferentially recognize remarkably subtle conformational states of GFP, inflicted by an 
internal protonation / deprotonation reaction. Such a capability to distinguish small functional 
states could be an important tool in the future, also in the context of modulating the 
properties of other proteins. 
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8.7 The Enhancer and the Minimizer Interfere with GFP 
Chromophore Environment 
To further test the structure-derived hypothesis that the interactions of the two nanobodies 
stabilize the neutral (Minimizer) or the ionized state of the chromophore (Enhancer), 
fluorescence absorption spectra were analyzed (Figure 41A and B). In support of this model, 
the Enhancer increases absorption at 475 nm (wtGFP: 4 fold increase, eGFP: 1.5 fold 
increase) while reducing it at 395nm for both wtGFP and eGFP (wtGFP 1.2 fold decrease , 
eGFP: 3 fold decrease). The Minimizer modulates the absorption in an exactly opposite 
manner, reducing absorption at 475 nm (wtGFP: 1.5 decrease, eGFP: 5 fold decrease) and 
increasing it a 395 nm (wtGFP 1.4 fold increase; eGFP: 1.8 fold increase). Therefore, the 
readily observed fluorescence modulation upon nanobody binding is presumably due to a 
change in the absorption efficiency at different wavelengths, which correlates with the 
magnitude of fluorescence emission and can be attributed to the protonation state of the 
fluorophore. The nanobody induced structural changes in the chromophore environment are 
summarized in Figure 41C. 
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Figure 41: Nanobody-induced GFP spectroscopic changes.  
Absorption spectra of the unbound (grey) Minimizer-bound (orange) or Enhancer-bound (raspberry) wtGFP (A) 
or eGFP (B). The absorption at 395 nm corresponds to the protonated chromophore, absorption at 475nm to 
the anionic chromophore (see chemical notation above). (C) Schematic illustration of the nanobody-induced 
structural changes in the GFP chromophore environment. Distances between the chromophore and H148GFP 
are indicated. 
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9 Discussion 
9.1 Enhancer and Minimizer Modulate GFP Intensity 
in Living Cells  
By screening a selection of GFP binding proteins, two nanobodies were found, that reversibly 
modulate GFP fluorescence; one nanobody minimized GFP fluorescence about fivefold and 
displacement by a second nanobody caused a tenfold increase. Structural analysis of GFP-
nanobody complexes revealed that the two nanobodies induce and stabilize subtle opposing 
changes in the chromophore environment leading to drastically altered absorption properties. 
Since GFP is widely used as fluorescence marker in cell imaging, an application of the newly 
discovered phenomenon is highly desirable. The following paragraph describes the 
nanobody-induced modulation in living cells. These experiments were conducted in the 
laboratory of Prof. Leonhardt and Dr. Ulrich Rothbauer, in great parts by Jonas Helma.  
It was tested whether the nanobody-induced fluorescence modulation observed in vitro also 
occurs in vivo. To this end, human embryonic kidney (HEK) 293T cells with expression 
vectors encoding wtGFP or eGFP in combination were transfected with constructs encoding 
Enhancer, Minimizer or a Control nanobody fused to monomeric red fluorescent protein 
(mRFP). After two days of incubation combined excitation and emission scans of GFP 
fluorescence intensities were performed in living cells (Figure 42A and B). Indeed, both 
nanobodies-induced spectral changes of wtGFP and eGFP fluorescence in vivo were similar 
to the ones observed in vitro and described above. Co-expression of the Enhancer and its 
target increased the signal of wtGFP at least 2-fold, whereas co-expression of the Minimizer 
resulted in a more than 5-fold decrease (Figure 42C). The effects of the nanobodies on 
eGFP were not as drastic but show a similar tendency. Altogether, these data clearly 
demonstrate that Enhancer as well as Minimizer can be effectively applied to induce a 
fluorescence modulation of GFP in living cells. 
To obtain a concentration-independent measurement of Enhancer or Minimizer binding and 
to test whether subcellular differences can be detected, the induced shift of GFP absorption 
maxima from 405 nm to 488 nm was determined by ratio imaging. To this end, the Enhancer 
was tethered to the nuclear lamina by transfecting HeLa cells with an expression construct 
coding for an Enhancer-Lamin B1 fusion. After co-expressing wtGFP in excess, images were 
acquired with excitation at 405 nm and at 488 nm to detect relative differences in GFP 
fluorescence intensities at the nuclear lamina due to binding to locally immobilized Enhancer-
Lamin B1 nanobody fusion protein. Although GFP was bound and enriched at the nuclear 
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lamina, this structure was barely detectable after excitation at 405 nm, however, excitation at 
488 nm indeed lead to an increased signal at the nuclear lamina (Figure 42D). 
Subsequently, the presence of Enhancer at this distinct sub-cellular structure could be 
visualized by calculating the ratio between pixel intensities obtain at 405 nm and at 488 nm, 
displaying the ratio images in false color, thereby distinguishing bound from unbound GFP 
(Figure 42D). This example illustrates how fluorescence-modulating nanobodies enable 
novel optical readouts. 
 
Figure 42: The nanobody-induced fluorescence modulation is applicable in living cells.  
Binding of Minimizer and Enhancer shifts excitation and emission spectra for both, wtGFP (A) and eGFP (B) in 
vivo. (C) Enhancement and minimization factors for wtGFP (black bars) and eGFP (grey bars) fluorescence 
were calculated by comparing overall fluorescence intensities to expression levels in vivo. After coexpression 
of Minimizer a significant reduction of the fluorescence intensity of wtGFP as well as eGFP is observable. The 
presence of the Enhancer increases the fluorescence intensity of both wtGFP and eGFP. Values obtained for 
the control nanobody were set to 1. (D) Ratio imaging. Shown are cells expressing wtGFP, which is dispersedly 
distributed throughout the cell. The top-most cell coexpresses Enhancer fused to laminB1 (GBP1-Lamin-B1). 
While only a weak signal at the nuclear lamina is detectable with excitation at 405 nm the relative and absolute 
signal increased with excitation at 488 nm due to the absorption modulation induced by binding to the 
Enhancer. Bound and unbound GFP can be distinguished independent of the total concentration by matrix 
algebra, calculating the ratio between the signal intensities obtained with excitation at 488 nm and at 405 nm 
for every pixel. The 488/405 ratios are then displayed in a false color gradient from blue (bound) to yellow 
(unbound). Scale bar is 10 µm. 
These ratio-imaging experiments also served as an initial proof of principle, that the 
nanobodies were applicable in vivo.  
Next, it should be tested whether the fluorescence enhancement effect induced by binding of 
GFP to Enhancer localized in a defined subcellular compartment, could be used to track 
subcellular translocation events in a high throughput manner. As an example, the inducible 
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translocation of the human estrogen receptor (ER) was examined. In this system, hormone 
binding leads to a conformational change in the receptor that results in its dissociation from 
chaperone proteins and ultimately in the binding of the receptor as a homodimer to cognate 
sites in steroid-responsive genes in the nucleus (Kabat and Wu 1991; Tsai and O'Malley 
1994). This subcellular trafficking event can be induced by the synthetic steroid hormone 
tamoxifen and followed with a GFP-labeled receptor and high resolution fluorescence 
microscopy (Htun et al. 1999). Since this original procedure is based on single cell imaging it 
is poorly suited for high throughput analysis. However, it was reasoned that the fixed-
Enhancer tracking system would allow for a simple fluorescent readout, thus making a 
highthrouput setup applicable. To test our hypothesis, a mammalian (HeLa-Kyoto) cell line 
was generated that stably expresses nuclear localized Enhancer fused to mRFP (nls-
Enhancer). The newly constructed cell line was utilized to transiently co-express the steroid 
binding domain of the human estrogen receptor (ER286-595) fused to wtGFP (GFP-ER286-595). 
According to our prediction, translocation of this construct from the cytoplasm to the nucleus 
should be detectable by an increase of the GFP-fluorescence intensity upon binding of GFP 
to the nls-Enhancer in the nucleus (Figure 43A). Using fluorescence microscopy it was 
confirmed, that both constructs - GFP-ER286-595 and nls-Enhancer - are almost exclusively 
targeted to their designated compartment. Upon addition of tamoxifen to the medium, GFP-
ER286-595 inducibly translocates from the cytoplasm into the nucleus (Figure 43B). Entering 
the nucleus, GFP becomes accessible for binding to nls-Enhancer which indeed results in a 
threefold increase in GFP-fluorescence intensity (Figure 43C). Importantly, the translocation 
event can be followed in a statistically significant number of cells by scanning the 
fluorescence intensities of living cells in multi-well formats. Moreover the fluorescence 
enhancement is directly correlated with translocation efficiency. By quantifying the 
fluorescence intensities a clear dose-dependency of translocation upon addition of increasing 
amounts of tamoxifen was detected (Figure 43D). Moreover, since our assay uses living 
cells, it was possible to follow the dynamics of the translocation event over time. These data 
demonstrate that fluorescence modulating nanobodies are powerful tools to study subcellular 
re-localization, a key process of many signal transduction pathways, in real time, high 
throughput and in a quantitative manner. 
9.2 Modulation of GFP Fluorescence with Nanobodies – 
Future Perspectives  
The modulation of GFP fluorescence enables a number of new bioimaging applications. The 
expression and subcellular distribution of Minimizer and Enhancer can be detected by ratio 
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imaging, allowing the distinction of bound from unbound GFP. This indirect optical readout 
can be used as reporter for gene expression, virus infection and translocation assays. The 
nanobody-mediated enhancement of GFP fluorescence should also improve the tracing of 
low–abundant GFP fusion proteins in live cells as well as ultrahigh resolution microscopy. 
Recently, it was demonstrated that cellular structures can be imaged at sub-diffraction 
resolution by 3D structured illumination microscopy (3D-SIM, (Schermelleh et al. 2008)). To 
obtain ultrahigh resolution, this new microscopy technology, however, requires hundreds of 
images and thus mostly relies on bright synthetic chromophores. The signals obtained with 
GFP labeled proteins are barely sufficient. Therefore, any fluorescence enhancement by 
either co-expressed or subsequently added Enhancer nanobody would greatly facilitate 3D-
SIM. Translocation events play a central role in signal transduction and are therefore a prime 
target for drug screenings. Presently, translocations are either indirectly monitored with 
reporter gene assays that take at least a day or by microscopy which requires costly and 
technically demanding high throughput image acquisition and analysis tools. Our nanobody 
based assay can be performed with a simple plate reader and measures translocation as 
fluorescence enhancement after drug addition. The feasibility of this assay principle was 
demonstrated using the tamoxifen-induced nuclear translocation of the estrogen receptor. 
Besides steroid hormone receptors also notch type signaling in differentiation and cancer and 
presenilin / gamma secretase activity in Alzheimer’s disease could be directly monitored in 
cell based drug screens.  
This work also opens new perspectives as it exemplarily shows applications of nanobodies 
ranging from affinity purification and crystallization of proteins to the manipulation of 
conformational states and protein function in vitro and in vivo. Especially the detection and 
manipulation of alternative protein conformation in living cells enable novel types of studies in 
molecular and cellular biology. The functional relevance of alternative protein conformations 
is clearly illustrated by the prion protein. Here an experimental strategy to address the role of 
alternative protein conformations in cellular systems is demonstrated. The here presented 
results show that nanobodies can be generated to recognize, induce and stabilize alternative 
protein conformations and thus enable studies of functional properties of specific protein 
conformations in vitro and in vivo.  
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Figure 43: Cytoplasmic-nuclear translocation events can be detected by nanobody 
mediated fluorescence enhancement. 
(A) Schematic outline of the translocation assay: GFP-ER and nls-Enhancer are present in the cytoplasm and 
the nucleus, respectively. Addition of Tamoxifen induces translocation of GFP-ER to the nucleus where it to nls-
Enhancer leading to an increase of the fluorescence intensity. (B) Representative cells were analyzed by 
fluorescence microscopy (scale bar 10 µM). Untreated cells (-Tamoxifen, upper row) show an almost exclusive 
distribution of GFP-ER to the cytoplasm while the nls-Enhancer is localized in the nucleus. After addition of 
Tamoxifen (+Tamoxifen, lower row) GFP-ER co-localizes with nls-Enhancer in the nucleus. (C, D). Nucleo-
cytoplasmic translocation induced by Tamoxifen was assayed in a plate format in living cells. (C) After 
translocation of GFP-ER into the nucleus binding of nls-Enhancer leads to a 3-fold increase of the 
fluorescence intensity. (D) Detection of dose dependent translocation efficiency by measuring the fluorescence 
enhancement effect. Increasing concentrations of Tamoxifen are indicated. 
87 Summary 
10 Summary 
The development of the green fluorescent protein (GFP) and its spectral variants was a 
milestone-discovery and transformed cell biological research. Although a range of GFP 
variants have been engineered to date, the possibility to alter GFP fluorescence is still 
lacking. By screening a selection of GFP binding nanobodies two candidates were found, 
which were termed Minimizer and Enhancer nanobody, respectively. Remarkably, binding of 
these two nanobodies antagonistically influenced the fluorescence properties of GFP, 
constituting a reversible fluorescence switch. The Minimizer induced a 5-fold diminishment of 
GFP emission intensity which can be reversed by addition of Enhancer leading to an overall 
20-fold increase of fluorescence. Structural and spectroscopic analysis of the two GFP-
nanobody complexes revealed that only subtle changes in the chromophore environment 
were responsible for the drastically altered absorption properties. Furthermore, it was 
demonstrated that both nanobodies can modulate the fluorescence intensity of GFP-fusions 
in living cells. The nanobody induced fluorescence modulation could be detected by ratio 
imaging and used to measure expression and subcellular localization. Furthermore, the 
fluorescence modulation can be employed as cellular translocation assay. Cells expressing 
nuclear nanobodies showed increased fluorescence upon tamoxifen-induced translocation of 
GFP-labeled estrogen receptor, providing a simple readout for functional studies and drug 
screenings. This work demonstrates that alternative protein conformations can be 
manipulated and studied with nanobodies, making these binders a novel and attractive tool 
for future research. 
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